28/02/2023

Date	Journal	Title	Study type	Country	Authors	Link	Trial identifier	Intervention	Main question
20-Feb-22	JAMA	Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19 A Randomized Clinical Trial	RCT	USA	Naggie S., et al.	https://jamanetwork.com/journals/jama/fullarticle/2801827	NCT04885530	ivermectin	To evaluate the effectiveness of ivermectin at a maximum targeted dose of 600 µg/kg daily for 6 days, compared with placebo, for the treatment of early mild to moderate COVID-19.
21-Feb-23	Lancet Respiratory Medicine	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	meta-analysis	International (France)	Amstutz A., et al.	Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials - ScienceDirect	NA (EU-RESPONSE)	remdesivir	To assess the benefits and harms of remdesivir compared with placebo or usual care in these patients, and whether treatment effects differed between prespecified patient subgroups.
17-Feb-23	The Lancet Child & Adolescent Health	Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial	RCT	China	Gao L., et al.	https://www.sciencedirect.com/science/article/pii/S2352464222003765?via%3Dihub	NCT04961359 (phase 1) and NCT05109598 (phase 2)	ZF2001 is a recombinant protein subunit vaccine against SARS-CoV-2	To evaluate the safety and immunogenicity of ZF2001 in children and adolescents aged 3–17 years in China.
16-Feb-23	NEJM	Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age	RCT	International	Muñoz F.M., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2211031	NCT04816643	BNT162b2	To evaluate a safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children.
09-Feb-23	The Lancet Regional Health - Southeast Asia	Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India	RCT	India	Sajgure A., et al.	https://www.sciencedirect.com/science/article/pii/S2772368223000148?via%3Dihub	CTRI/2021/01/030477	Mycophenolate	To assess the safety and efficacy of mycophenolate in patients hospitalised with COVID-19.
09-Feb-23	NEJM	Early Treatment with Pegylated Interferon Lambda for Covid-19	RCT	International (Together study)	Reis G., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2209760	NCT04727424. opens in new tab.	Pegylated Interferon Lambda	To assess the efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19).
08-Feb-23	BMJ	Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study	Test negative design study.	Canada	Jorgensen S.C.J., et al.	https://www.bmj.com/content/380/bmj-2022-074035	NA	Maternal mRNA covid-19 vaccination during pregnancy.	To estimate the effectiveness of maternal mRNA covid-19 vaccination during pregnancy against delta and omicron severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and hospital admission in infants.
08-Feb-23	Clinical Infectious Diseases	Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 Omicron period — United States, January 1, 2022–March 31, 2022	data registry analysis	USA	Kompaniyets L., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad063/7030940	NA	Ad26.COV2.S (Johnson & Johnson) primary dose, heterologous boosting with BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) mRNA vaccines	This study of 18.9 million adults aged ≥18 years assessed relative vaccine effectiveness (rVE) in three recipient cohorts: (1) primary Ad26.COV2.S vaccine and Ad26.COV2.S booster (two Ad26.COV2.S), (2) primary Ad26.COV2.S vaccine and mRNA booster (Ad26.COV2.S+mRNA), (3) two doses of primary mRNA vaccine and mRNA booster (three mRNA).
06-Feb-23	The Lancet Regional Health - Western Pacific	Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study	RCT	China	Liu J., et al.	https://www.sciencedirect.com/science/article/pii/S2666606523000123?via%3Dihub	grant number: 82172152, 81873944	Nirmatrelvir plus ritonavir (Paxlovid)	To study the efficacy and safety of Paxlovid in hospitalized adult patients with SARS-Cov-2 (Omicron BA.2.2 variant) infection and severe comorbidities.
31-Jan-23	Lancet preprint	Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial	RCT	India	Singh C., et al.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771	NCT05522335	iNCOVACC® intranasal vaccine	interim immunogenicity and safety of an intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154, iNCOVACC®) in healthy adults compared with licensed intramuscular vaccine (Covaxin®).
02-Feb-23	Clinical Microbiology and Infection	Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial	RCT	International (BCG-PRIME study group)	Koekenbier E.L., et al.	https://www.sciencedirect.com/science/article/pii/S1198743X23000447?via%3Dihub	NCT04537663	Bacillus Calmette-Guérin (BCG) vaccination	To test whether Bacillus Calmette-Guérin (BCG) vaccination would reduce the incidence of COVID-19 and other respiratory tract infections (RTIs) in older adults with one or more comorbidities.
03-Feb-23	The Lancet Child & Adolescent Health	Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial	RCT	Switzerland	Welzel et al.	https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00020-2/fulltext	NCT04826588	methylprednisolone or immunoglobulins	Assess the effectiveness of intravenous methylprednisolone compared with intravenous immunoglobulins.
16-Feb-23	NEJM	Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age	RCT	Multinational	Muñoz et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2211031?query=featured_home	NCT04816643	BNT162b2 vaccine	Immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age.

23-Feb-23	International Journal of Infectious Diseases	The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2 - The results of ProBCG: A Multicenter Randomized Clinical Trial in Brazil	RCT	Brazil	Santos et al.	https://www.sciencedirect.com/science/article/pii/S1201971223000656?via%3Dihub	NCT04659941	BCG vaccine	Study aimed to assess the effect of BCG vaccine administration on the cumulative incidence of SARS-CoV-2 infection.
16-Feb-23	Pharmaceutics	Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial	RCT	Spain	Castro-Balado	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966500/	EudraCT number: 2020-001760-29	inhaled 65° ethanol through an oxygen flow	The efficacy and safety of inhaled ethanol in older adults at initial phases of infection.
24-Feb-23	BMC Infectious Diseases	Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years	RCT	Iran	Gholami et al.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08079-1	IRCT20210206050259N1	vaccine FAKHRAVAC	Safety and efficacy of FAKHRAVAC vaccine in adults
07-Dec-22	Clinical Infectious Diseases	Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study	RCT	Japan	Mukae H., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac933/6881001	jRCT2031210350	Ensitrelvir fumaric acid	To evaluate the efficacy as the the change from baseline in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer on day 4 and time-weighted average change from baseline up to 120 hours in the total score of predefined 12 COVID-19 symptoms. Safety was assessed through adverse events.
13-Dec-22	Nature	Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up	open label nonRCT	International	Canetti M., et al.	https://www.nature.com/articles/s41467-022-35480-2	NCT05231005 and NCT05230953	BNT162b2 and mRNA1273	To assess the safety, immunogenicity, and efficacy of the fourth-dose vaccines, either 50 µg of mRNA1273 or 30 µg of BNT162b2, in health care workers.
14-Dec-22	JAMA Netw. Open	Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age	test-negative case-control study	US	Khan F.L., et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799549	NA	BNT162b2	To estimate vaccine effectiveness (VE) and durability of BNT162b2 against infection with the Delta and Omicron variants of SARS-CoV-2 among 5- to 11-year-old children.
14-Dec-22	JAMA	Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial	RCT	International	Higgins A., et al.	https://jamanetwork.com/journals/jama/fullarticle/2799870	NCT02735707	Immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401)	What is the effect of treatment for critically ill patients with COVID-19 on longer-term mortality, disability, and health-related quality of life?
19-Dec-22	medRXiv	Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial	RCT	Netherlands	Tan H.C., et al.	Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial | medRxiv	Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial	Bivalent Omicron BA.1 booster vaccination	To compare immunogenicity and reactogenicity of mRNA-based bivalent Omicron BA.1 vaccines in individuals who were primed with adenovirus- or mRNA-based vaccines.
22-Dec-22	Lancet	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial	RCT	International	Butler C.C. et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext	ISRCTN number 30448031	Molnupiravir	To establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.
26-Dec-22	eClinicalMedicine	Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial	RCT	Greece, Italy	Akinosoglou K., et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00514-4/fulltext	NCT04680949	Anakinra	To provide a subgroup analyses and long-term outcomes of patients using anakinra.
28-Dec-22	NEJM	VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19	RCT	China	Cao Z., et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2208822	NCT05341609	VV116 vs. Nirmatrelvir–Ritonavir	To evaluate the safety and efficacy VV116.
11-Jan-22	Lancet Infectious Diseases	Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia	RCT	International	Fadlyana E., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00800-3/fulltext#%20	NA	Coronavac	To evaluate the immunogenicity and safety of three potential booster vaccines administered as a full-dose homologous booster or full-dose or half-dose heterologous boosters among individuals primed with CoronaVac
10-Jan-23	BMC Critical care	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial	RCT	International	Trøseid M., et al.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04205-8	NCT04891133	baricitinib	To evaluate the efficacy of baricitinib in severe/critical COVID patients.
12-Jan-23	JAMA	Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19	RCT	USA	McCarthy M.W., et al.	https://jamanetwork.com/journals/jama/fullarticle/2800448	NCT04885530	Fluvoxamin	Does 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, shorten symptom duration among adult (aged ≥30 years) outpatients with symptomatic mild to moderate COVID-19?
18-Jan-23	The Lancet Microbe	First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2	non randomized CT	International	Smit M.J., et al.	https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00337-8/fulltext	NCT04839146	ABNCoV2 vaccine	To clinically test a modular Capsid virus-like particles (cVLP) COVID-19 vaccine in individuals who were naive to SARS-CoV-2.

19-Jan-23	Nature	Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial	RCT	USA Mexico	Fong Y., et al.	https://www.nature.com/articles/s41467-022-35768-3	NCT04611802	NVX-CoV2373 (Novavax) SARS-CoV-2 vaccine	To evaluate a safety and efficacy of NVX-CoV2373 vaccine against PCR-confirmed symptomatic COVID-19
3-Dec-22	eBioMedicine	Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial	RCT	United Arab Emirates, Dubai	Hannawi et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00568-0/fulltext#%20	NCT05043311	SCTV01C vaccine	Assess the safety and immunogenicity of SCTV01C
31-Dec-22	The Lancet Regional Health Americas	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial	RCT	Cuba	Toledo-Romaní et al.	https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00240-X/fulltext	RPCEC00000354 (Cuban Registry?)	SOBERANA-02 vaccine	Evaluate the safety and efficacy of two immunisation regimes: two doses of SOBERANA-02 and a heterologous three-dose combination with SOBERANA-Plus added to it.
14-Dec-22	The Lancet Respiratory Medicine	Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care	RCT	Multinational (UK, Brazil, Mexico)	Shah et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00412-X/fulltext	NCT04373733	Favipiravir	The safety and efficacy of oral favipiravir in patients hospitalised with COVID-19
19-Jan-23	NEJM	Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years	RCT	USA	Winokur et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2213082?query=featured_coronavirus	NCT04955626	monovalent or bivalent omicron BA.1–adapted vaccines	To determine superiority and noninferiority of the BA.1-adapted vaccines to BNT162b2 vaccine
22-Nov-22	Clinical Infectious Diseases	AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19, STORM CHASER Study	RCT phase III	USA/UK	Levin MJ et al.	https://pubmed.ncbi.nlm.nih.gov/36411267/	NCT04625972	Tixagevimab/Cilgavimab	To report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19)
16-Nov-22	BMJ	Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial, CLARITY trial	RCT phase III	India, Australia	Zheng B. et al.	https://www.bmj.com/content/379/bmj-2022-072175	NCT04394117	telmisartan 40 mg/day	To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.
15-Nov-22	Annals of Internal Medicine Enter words / phrases / DOI / ISBN / keywords / authors / etc	Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy	cohort study	USA	McCreary EK. Et al.	https://www.acpjournals.org/doi/10.7326/M22-1329	NA	sotrovimab (69%; n = 382) compared with casirivimab and imdevimab (20%; n = 110) and bamlanivimab and etesevimab (11%; n = 60).	To determine the frequency of drug-related adverse events and obstetric-associated safety outcomes after treatment with mAb compared with no mAb treatment of pregnant persons, and the association between mAb treatment and a composite of 28-day COVID-19–related hospital admission or emergency department (ED) visit, COVID-19–associated delivery, or mortality.
14-Nov-22	Nature Communications	Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents	RCT phase II	China	Wang Z. et al.	https://www.nature.com/articles/s41467-022-34280-y	NCT04551547	CoronaVac	To assess the safety and immunogenicity of a third dose of CoronaVac
11-Nov-22	Clinical Infectious Diseases	VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical study	RCT phase III	Germany	Blossey AM et a.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac881/6821343	NCT04435379	VPM1002 (a genetically modified BCG)	To evaluate the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including COVID-19 in an elderly population.
04-Nov-22	Clinical Infectious Diseases	Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial	RCT phase III	Tunisian	Abdallah SB et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac807/6795268	NCT05212480	zinc	To examine zinc efficacy in adult patients with COVID-19 infection.
02-Nov-22	The Lancet Regional Health - Europe	High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial	RCT phase II	Denmark	Hansen KS et al.	https://www.sciencedirect.com/science/article/pii/S2666776222002356?via%3Dihub	NCT04960215, 2020-005961-16	coenzym Q10	To evaluate if coenzyme Q10 (CoQ10) can improve mitochondrial function, we examined whether high-dose CoQ10 can reduce the number and/or severity of PCC-related symptoms.
Dec-22	eBioMedicine	Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial	RCT Phase II	International	Chandiwana N et al.	https://www.sciencedirect.com/science/article/pii/S2352396422005047?via%3Dihub	NCT04532931	standard-of-care (SOC) with paracetamol, or SOC plus artesunate-amodiaquine (ASAQ), pyronaridine-artesunate (PA), favipiravir plus nitazoxanide (FPV + NTZ), or sofosbuvir-daclatasvir (SOF-DCV)	To investigate four repurposed anti-infective drug regimens in outpatients with COVID-19.
22-Nov-22	Vaccine	Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study	RCT phase II/III	India	Thuluvu S et al.	https://www.sciencedirect.com/science/article/pii/S0264410X22013081?via%3Dihub	CTRI/2021/10/037066	CORBEVAX™ vaccine	To evaluate the safety, reactogenicity, tolerability and immunogenicity of CORBEVAX™ vaccine in children and adolescents of either gender between <18 to ≥12 years of age in Phase-2 and <18 to ≥5 years of age in Phase-Phase-2/Phase-3 with placebo as a control.
20-Nov-2022	MedRxiv	Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial	RCT	USA	Alvez et al.	https://www.medrxiv.org/content/10.1101/2022.11.18.22282414v1.full.pdf+html	NCT04368988	VX-CoV2373 vaccine	Immunogenicity and safety of fourth dose of NVX-CoV2373 vaccine

22-Nov-22	MedRxiv	Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial	RCT	China	Liu et al.	https://www.medrxiv.org/content/10.1101/2022.11.20.22282565v1.full.pdf+html	NCT05463419	PIKA-adjuvanted recombinant SARS-C0V-2 Spike (S) protein subunit vaccine	The safety and immunogenicity of the PIKA-adjuvanted recombinant SARS-C0V-2 Spike (S) protein subunit vaccine
01-Dec-22	MedRxiv	Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial	RCT	USA	McCarthy	https://www.medrxiv.org/content/10.1101/2022.10.17.22281178v2.full-text	NCT04885530	Fluvoxamine	The effectivness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate COVID-19
13-Sep-22	The Lancet Regional Health Western Pacific	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial	RCT	China	Hui et al.	https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00201-2/fulltext	NCT04649021	BNT162b2 vaccine	Immunogenicity and safety of BNT162b2 vaccine
20-Oct-22	The Lancet Infectious Diseases	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial	Post hoc analysis of RCT	South Africa	Madhi et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00596-5/fulltext	NCT04444674,	NA	Evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody responses through to 180 days
20-Oct-22	eCinicalMedicine	Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial	RCT	Australia	McMahon et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00433-3/fulltext#%20	NCT04445467	favipiravir	Assess antiviral effect of favipiravir in the course of infection SARS-CoV-2
19-OCT-22	NEJM	Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age - KidCOVE Study Group	RCT	USA	Anderson J.E., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2209367	NCT04796896	mRNA-1273 vaccine	To evaluate the safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children.
19-OCT-22	Lancet Inf Dis	Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial - AGILE CST-2 Study Group	RCT	UK	Khoo S.H., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00644-2/fulltext	NCT04746183	molnupiravir	To evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19.
18-OCT-22	Nature Communications	Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial	long-term follow-up of a randomized trial	International	Nevalainen O.P.O., et al.	https://www.nature.com/articles/s41467-022-33825-5	NCT04978259	remdesivir	To evaluate the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19.
10-Oct-22	Lancet Resp Med	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial	RCT	Canada	Eikelboom JW	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00298-3/fulltext	NCT04324463	colchicine, rivaroxaban, and aspirin	To evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.
10-OCT-22	eBioMedicine	Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial	RCT	UK	Madhavan M., et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00480-7/fulltext	NCT04816019	intranasal vaccination with ChAdOx1 nCoV-19	To evaluate the tolerability and safety of intranasal ChAdOx1 nCoV-19 in healthy volunteers.
10-Oct-22	Clinical Infectious Diseases	Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial	RCT	USA	Heath P.T., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac803/6754597	NCT04611802	NVX-CoV2373 COVID-19 Vaccine	To evaluate a safety and efficacy of NVX-CoV2373 for the prevention of Covid-19.
6-OCT-22	Nature Med	Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial	RCT	USA	Chalkias S., et al.	https://www.nature.com/articles/s41591-022-02031-7	NCT04927065	mRNA-1273.211 vaccine	interim results from an ongoing, open-label phase 2/3 trial evaluating the safety and immunogenicity of the bivalent Coronavirus Disease 2019 (COVID-19) vaccine candidate mRNA-1273.211, which contains equal mRNA amounts encoding the ancestral SARS-CoV-2 and Beta variant spike proteins, as 50-µg (n = 300) and 100-µg (n = 595) first booster doses administered approximately 8.7–9.7 months after the mRNA-1273 primary vaccine series
6-OCT-22	preprint	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial - PANORAMIC Trial	RCT	UK	Butler C.C., et al.	http://freepdfhosting.com/20cdd6cdfe.pdf	ISRCTN30448031	molnupiravir	To determine whether molnupiravir added to usual care reduced hospital admissions/deaths among people at higher risk from COVID-19, and here report our preliminary analyses
28-SEP-22	eClinicalMedicine	Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial	RCT	China	Zhang Y., et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00410-2/fulltext	ChiCTR2200057758	CoronaVac	More effective vaccine candidates against variants of concern as a booster dose are needed in people primed with two-dose inactivated COVID-19 vaccines.
01-OCT-22	eClinicalMedicine	Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial	RCT	France	Kalfon P., et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00393-5/fulltext	NCT04357457	almitrine	To evaluate if almitrine can reduce the risk for mechanical ventilation (MV) in patients with COVID-19 pneumonia. Our primary objective was to determine the effect of almitrine on the need for MV at day 7.

13-SEP-22	Lancet Inf Dis	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial	RCT	Belgium	Hardt K., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00506-0/fulltext	NCT04614948	Ad26.COV2.S vaccine	To investigate the efficacy, safety, and immunogenicity of the Ad26.COV2.S vaccine (Janssen) as primary vaccination plus a booster dose.
09-SEP-22	CMI	Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial	RCT		Tabarsi P., et al.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00464-5/fulltext	NCT05005559	SpikoGen	To investigate the efficacy and safety of SpikoGen®, a subunit coronavirus disease 2019 (COVID-19) vaccine composed of a recombinant severe acute respiratory syndrome coronavirus 2 spike protein with Advax-CpG55.2™ adjuvant.
22-Aug-22	Nature Commun	Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19	RCT	USA	Chew K.W., et al.	https://www.nature.com/articles/s41467-022-32551-2	NCT04518410	bamlanivimab	To assess safety, antiviral, and clinical efficacy of bamlanivimab (randomized controlled trial ACTIV-2/A5401).
18-Aug-22	NEJM	Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19	RCT	USA	Bramante C.T., et al	https://www.nejm.org/doi/10.1056/NEJMoa2201662	NCT04510194. opens in new tab	metformin, ivermectin, and fluvoxamine	To test the effectiveness of three repurposed drugs —metformin, ivermectin, and fluvoxamine — in preventing serious SARS-CoV-2 infection in nonhospitalized adults.
12-Aug-22	eBioMedicine	Evaluation of safety and immunogenicity of receptor-binding domain□based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials	RCT	India	Thuluva S., et al.	https://www.sciencedirect.com/science/article/pii/S2352396422003991?via%3Dihub	CTRI/2021/06/034014 and CTRI/2020/11/029032	Corbevax	To assess the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine
10-Aug-22	Lancet Infect Dis.	Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo□controlled, phase 2 trial	RCT	USA	Mallory R.M., et al.	https://www.sciencedirect.com/science/article/pii/S1473309922004200?via%3Dihub	NCT04368988	NVX-CoV2373 vaccine	To assess the immunogenicity and safety of a homologous booster dose of Novavax's SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373)
30-Jul-22	Lancet	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis	RCT	UK	RECOVERY Collaborative Group	https://www.sciencedirect.com/science/article/pii/S0140673622011096?via%3Dihub	NCT04381936)	baricitinib	To evaluate the use of baricitinib, a JAK1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
05-Jul-22	JAMA Intern Med.	High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory FailureThe COVIDICUS Randomized Clinical Trial	RCT	France	Bouadma L., et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2794040	NCT04344730; 2020-001457-43	Dexamethasone and Oxygen Support Strategies	To assess the benefit of high-dose dexamethasone compared with standard of care dexamethasone, and to assess the benefit of high-flow nasal oxygen (HFNO2) or continuous positive airway pressure (CPAP) compared with oxygen support standard of care (O2SC)
08-Jul-22	Lancet Respir Med	Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID□19: a randomised, double□blind, phase 3 tria	RCT	USA	Holland T. L., et al. (ACTIV-3 / TICO group)	https://www.sciencedirect.com/science/article/pii/S2213260022002156?via%3Dihub	NCT04501978	Tixagevimab–cilgavimab	To compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care.
05-Jul-22	Lancet Infect Dis.	Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial		USA	Herman G.A., et al.	https://www.sciencedirect.com/science/article/pii/S1473309922004169?via%3Dihub	NCT04452318	casirivimab and imdevimab	To present additional results from the monoclonal antibody combination casirivimab and imdevimab (CAS + IMD), including the 7-month follow-up period (months 2–8), providing additional insights about the potential for efficacy in pre-exposure prophylaxis settings.
05-Jul-22	Ann Intern Med.	Antinucleocapsid Antibodies After SARS□CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial	RCT	Canada/USA	Follmann D., et al.	https://www.acpjournals.org/doi/10.7326/M22-1300	NCT04470427	Moderna vaccine	To evaluate antinucleocapsid antibody (anti-N Ab) seropositivity in mRNA-1273 (Moderna) vaccinees with breakthrough SARS-CoV-2 infection
29-Jun-22	NEJM	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine	RCT	France	Launay O., et al.	https://www.nejm.org/doi/10.1056/NEJMc2206711	NCT05124171; 2021-004550-33	vaccine BNT162b2 (Pfizer–BioNTech)	To assess the immunogenicity and safety of two adjuvanted recombinant vaccines and the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech) administered as a booster
12-Jun-22	Nature Commun	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial	RCT	International	Al Kaabi N., et al.	https://www.nature.com/articles/s41467-022-31379-0	NCT05069129	NVSI-06-08 vaccine, NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen.	To evaluate the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in BBIBP-CorV recipients in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates.
7-Sep-22	The Lancet Respiratory Medicine	Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	RCT	Multinational	Vlaar et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00297-1/fulltext	NCT04333420	vilobelimab	To determine whether vilobelimab in addition to standard of care improves survival outcomes in invasively mechanically ventilated patients with COVID-19
5-Sep-22	The Lancet Infectious Diseases	Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial	RCT	Multinational	Lazarus et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00502-3/fulltext#%20	NCT04864561	VLA2001 vaccine	To assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccine.

5-Sep-22	The Lancet Respiratory Medicine	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial	RCT	UK	Keir et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00261-2/fulltext	ISRCTN30564012	brensocatib	Whether brensocatib, an inhibitor of dipeptidyl peptidase-1 (DPP-1; an enzyme responsible for the activation of neutrophil serine proteases), would improve outcomes in patients hospitalised with COVID-19.
6-Jul-22	eBioMedicine	Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial	RCT	USA	Robbins et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00319-X/fulltext#%20	NCT04569786	V590 vaccine	Safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine candidate
1-Jul-22	eClinicIMedicine	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study	RCT	Spain	García-Pérez et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00259-0/fulltext	NCT04860739, EudraCT 2021-001978-37	ChAdOx1-S/BNT162b2	To assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination
16-Jun-22	Lancet Infect Dis.	Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non‐randomised, age de‐escalation phase 2/3 study	RCT II/III Phase	India	Vadrevu K.M., et al	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00307-3/fulltext	NCT04918797	inactivated SARS-CoV-2 vaccine (BBV152) (COVAXIN; Bharat Biotech International, Hyderabad, India)	To assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, BBV152 (COVAXIN; Bharat Biotech International), in children aged 2–18 years.
11-Jun-22	Lancet	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single‐blind, randomised, controlled trial	RCT II Phase	UK	Li G., et al	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00770-X/fulltext	ISRCTN (15638344).	ChAdOx1 nCoV-19 (AZD1222) vaccine	To evaluate safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years
07-Jun-22	Ann Intern Med.	Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19	Analysis of the randomized, double-blind, placebo‐controlled phase 3 component of MOVe-OUT	USA	Johnson G. M, et al	https://www.acpjournals.org/doi/10.7326/M22-0729	NCT04575597	Molnupiravir	to identify further potential clinical benefits of molnupiravir versus placebo.
08-Jun-22	Lancet Resp Med	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial	RCT	UK	Vadrevu K.M., et al	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00163-1/fulltext	ISRCTN registry, 69254139 (EudraCT 2020–005085–33).	BNT162b2 and ChAdOx1 nCoV-19	To report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals on reactogenicity and the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 and ChAdOx1 nCoV-19.
07-Jun-21	Lancet Resp Med.	Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	RCT III Phase	UK/USA	Montgomery H., et al	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00180-1/fulltext	NCT04723394.	tixagevimab–cilgavimab	To evaluate the safety and efficacy of tixagevimab–cilgavimab in preventing progression to severe COVID-19 or death.
02-Jun-22	Lancet Infect Dis.	Effectiveness of mRNA vaccine boosters against infection with the SARS‐CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study	cohort study	Spain	Monge S., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00292-4/fulltext	NA	mRNA vaccine boosters	To estimate the effectiveness of mRNA-based vaccine boosters (third dose) against infection with the omicron variant by age, sex, time since complete vaccination, type of primary vaccine, and type of booster.
26-May-22	Lancet Respir Med	Safety and immunogenicity of a live‐attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo‐controlled, phase 1 and 2 trials	RCT phase I/II	China	Zhu F., et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00131-X/fulltext	ChiCTR2000037782, ChiCTR2000039715, and ChiCTR2100048316	a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine	Evaluation the safety and immunogenicity of a live-attenuated influenza virus vector-based SARS-CoV-2 vaccine (dNS1-RBD) administered by intranasal spray in healthy adults.
25-May-22	NEJM	Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron	Test-negative, case–control analysis	USA	Accorsi E. K., et a	https://www.nejm.org/doi/10.1056/NEJMc2203165	NA	Homologous and Heterologous Covid-19 Boosters vaccines	to obtain data from the general adult population and on vaccine effectiveness over time of 4 vaccine regimens.
23-May-22	Lancet Respir Med	Baricitinib versus dexamethasone for adults hospitalised with COVID‐19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial	RCT	USA	Wolfe C.R., et al	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00088-1/fulltext	NCT04640168.	Baricitinib versus dexamethasone	To assess the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID‐19.
03-Jun-22	eClinicalMedicine	Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials	Meta-analysis or RCT	USA	Selvaraj et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00219-X/fulltext	NA	NA	Meta-analysis of RCTs assessing the role of baricitinib in hospitalised patients with COVID-19
03-Jun-22	eClinicalMedicine	Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial	RCT	Japan	Terada	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00214-0/fulltext#%20	jRCTs031200196	favipiravir monotherapy or favipiravir + camostat + ciclesonide combination therapy	The role of baricitinib in hospitalised patients with COVID-19
9-Jun-22	The Lancet Respiratory Medicine	Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial	RCT	Cuba	Ochoa-Azze et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00100-X/fulltext	RPCEC00000366-En	FINLAY-FR-1A vaccine	The efficacy and safety of FINLAY-FR-1A vaccine in convalescent participants

17-May-22	Clin Infect Dis.	A Single Dose of BNT162b2 mRNA Vaccine Induces Airway Immunity in SARS□CoV-2 Naive and recovered COVID-19 subjects	longitudinal study	France	Martinuzzi E., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac378/6586846	NCT04418206	a booster injection of BNT162b2	To investigate whether a booster injection of BNT162b2 promotes stronger mucosal immune responses following prior mucosal infection compared to a mucosally naive subject.
11-May-22	NEJM	Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age	RCT	USA	Creech C.B., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2203315	NCT04796896. opens in new tab	mRNA-1273 vaccine	To evaluate safety, immunogenicity, and efficacy of the mRNA□1273 vaccine in children 6 to 11 years of age are unknown.
09-May-22	Lancet Infect Dis	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA□1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV□19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial	RCT	UK	Munro A.P.S., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00271-7/fulltext	ISRCTN, 73765130	fourth-dose booster dose of vaccine	To investigate the safety, reactogenicity, and immunogenicity of fourth-dose booster dose of vaccine against COVID-19.
09-May-22	Nature Immunol.	Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose	prospective cohort study	Israel/US	Lustig Y., et al.	https://www.nature.com/articles/s41590-022-01212-3	NA	the effectiveness and safety of the third BNT162b	To assess immunogenicity, vaccine effectiveness and safety of the third BNT162b2 vaccine dose in a prospective cohort study of 12,413 healthcare workers (HCWs).
06-May-22	Clin Microbiol Infect.	An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results	RCT	International	Ader F., et al.	https://linkinghub.elsevier.com/retrieve/pii/S1198743X22002245	NCT04315948	lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine	To report final analysis, after completion of data monitoring, of the DisCoVeRy trial evaluating efficacy of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
04-My-22	NEJM	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine	RCT	International	Hager K.J., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2201300	NCT04636697	CoVLP+AS03 vaccine	to evaluate a candidate vaccine based on Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of SARS-CoV-2 that are combined with an adjuvant (Adjuvant System 03 [AS03]).
04-May-22	NEJM	Efficacy and Safety of the RBD-Dimer–Based Covid□19 Vaccine ZF2001 in Adults	RCT	China	Dai L., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2202261	NCT04646590	ZF2001 vaccine	To evaluate efficacy and confirm safety of the ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain of SARS-CoV- 2 and aluminum hydroxide as an adjuvant.
02-May-22	Lancet	Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses	RCT	International	WHO Solidarity Trial Consortium	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00519-0/fulltext	NCT04315948	remdesivir	To report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date.
01-May-22	Lancet HIV	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	RCT	South Africa	Mahdi S. A., et al	https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00041-8/fulltext	NCT04533399	NVX-CoV2373; Novavax	To evaluate the safety and immunogenicity of a Matrix-M adjuvanted recombinant spike protein nanoparticle COVID-19 vaccine (NVX-CoV2373; Novavax) in HIV-negative people and people living with HIV-1.
29-Apr-22	Lancet Reg Health Eur	Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study	phase IV	France	Ouldali N., et al.	https://www.sciencedirect.com/science/article/pii/S2666776222000862?via%3Dihub	NA	mRNA vaccine	To assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children.
27-Apr-22	Nature Commun.	Safety and serum distribution of anti-SARS□CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection	Phase I	Italy	Lanini S., et al	https://www.nature.com/articles/s41467-022-29909-x	NCT04932850	MAD0004J08 is a potent Fc-engineered monoclonal antibody (mAb) able to neutralize in vitro all current SARS-CoV-2 VoCs including omicron variant even if with significantly reduced potency.	To evaluate data obtained from the first 30 days of a phase 1 clinical study
14-Apr-22	The Lancet Rheumatology	Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis	population-based analysis	Canada	Widdifield et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00096-0/fulltext	NA	NA	What is COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases
20-Apr-22	NEJM	Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19	RCT	Multinational	Ustianowski et al.	chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116620?articleTools=true	NCT04625725	tixagevimab and cilgavimab (AZD7442)	Safety and efficacy of tixagevimab and cilgavimab
13-Apr-22	NEJM	Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	RWD - Registry	USA	Magen O., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2201688	NA	fourth dose of the BNT162b2 vaccine	To evaluate the early effectiveness of a fourth dose of the BNT162b2 vaccine for the prevention of Covid-19–related outcomes.
08-Apr-22	Lancet Infect Dis	COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study	Longitudinal, prospective, community-based study	UK	Menni C., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00146-3/fulltext	NA	BNT162b2, ChAdOx1 nCoV-19, mRNA-1273 vaccine	To investigate COVID-19 primary vaccine series effectiveness and its waning, and the safety and effectiveness of booster doses, in a UK community setting

07-Apr-22	Lancet	Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study	Prospective longitudinal observational study	UK	Menni C., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00327-0/fulltext	NA	BNT162b2, ChAdOx1 nCoV-19, mRNA-1273 vaccine	To quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population
06-Apr-22	NEJM	Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers	Cohort: health care personnel first responders, and other essential and frontline workers	USA	Yoon S.K., et al.	https://www.nejm.org/doi/10.1056/NEJMc2201821	NA	three doses of BNT162b2 (administered in 74%), mRNA-1273 (in 24%), or a combination of the two vaccines (in 2%).	To report effectiveness of two or three doses of a mRNA vaccine against infection caused by SARS-CoV-2 omicron and delta variants
05-Apr-22	NEJM	Protection by a Fourth Dose of BNT162b2 against Omicron in Israel	RWD - Israeli Ministry of Health database	Israel	Bar-On Y.M., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2201570	NA	Fourth Dose of BNT162b2	To evaluate the effect of the fourth dose on rates of confirmed SARS-CoV-2 infection and of severe Covid-19 in persons 60 years of age or older.
31-Mar-22	Lancet Infect Dis	Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	Retrospective cohort study - Swedish Vaccination Register and data on documented SARS-CoV-2 infections were collected from the SmiNet register; both registers are managed by the Public Health Agency of Sweden.	Sweden	Nordström P., et al	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00143-8/fulltext	NA	previous infection and having received a single dose of either ChAdOx1 nCoV-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) either before or after infection at baseline.	To investigate the long-term protection from a previous infection (natural immunity) and whether natural immunity plus vaccination (hybrid immunity) was associated with additional protection.
30-Mar-22	NEJM	BNT162b2 Protection against the Omicron Variant in Children and Adolescents	case–control, test-negative design	USA	Price A.M., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2202826	NA	BNT162b2 vaccine	To study immune evasion and the duration of protection from vaccines against Covid-19 due to SARS-CoV-2 B.1.1.529 (omicron) variant in children and adolescents.
30-Apr-22	NEJM	Effect of Early Treatment with Ivermectin among Patients with Covid-19	RCt	International	Reis G., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2115869	NCT04727424	ivermectin	To evaluate efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic Covid-19
02-Mar-22	NEJM	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant	test-negative case–control design	UK	Andrews N., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2119451	NA	BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine	To estimate vaccine effectiveness against symptomatic disease caused by the omicron and delta (B.1.617.2) variants in England.
02-Mar-22	JAMA Netw Open	Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations	cohort study	France	Botton J., et al	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789572	NA	Ad26.COV2.S vaccine and BNT162b2 vaccine	To compare the effectiveness of full vaccination with Ad26.COV2.S vs BNT162b2 against COVID-19–related hospitalization.
02-Mar-22	Clin Infect Dis.	Antibody response in immunocompromised patients after the administration of SARS□CoV-2 vaccine BNT162b2 or mRNA-1273: A randomised controlled trial	RCT	Switzerland	Speich B., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac169/6540899	NCT04805125	BNT162b2 and mRNA-1273 vaccine	BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent SARS-CoV-2 infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking.
28-Feb-22	JAMA Netw Open	Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids	Bayesian random-effects meta-analysis	Brasil	Albuquerque A. M., et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789444	NA	tocilizumab and respiratory support	To use bayesian methods to assess the magnitude of mortality benefit associated with tocilizumab and the differences between respiratory support subgroups in hospitalized patients with COVID-19.
26-Feb-22	Clin Infect Dis.	Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial	RCT	USA	Sivapalasingam S., et al	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac153/6537638	NCT04315298	sarilumab	This study evaluated the efficacy and safety of sarilumab, an anti–IL□6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19.
25-Feb-22	JAMA Neurol.	Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab	cohort study	Switzerland	Madelon N., et al.	https://jamanetwork.com/journals/jamaneurology/fullarticle/2789588	NA	Third Dose of mRNA COVID-19 Vaccine and ocrelizumab	To determine T-cell responses to the Omicron spike protein in anti-CD20–treated patients with multiple sclerosis (MS) before and after a third mRNA COVID-19 vaccination.
21-Feb-22	Lancet	Duration of effectiveness of vaccines against SARS□CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression	meta-analysis	Internationa	Feikin D. R., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00152-0/fulltext	NA	COVID-19 vaccines	To systematically review the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination

23-Mar-22	NEJM	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine	RCT	Brazil/USA	Moreira E.D., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2200674	NCT04955626	The third dose of the BNT162b2 vaccine	To evaluate safety and efficacy of offering a third (booster) dose in persons 16 years of age or older.
23-Mar-22	Nature Commun	Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2	cohort study based on linked routinely collected data available to the Public Health Secretariat of Catalonia	International	Hermosilla E., et al.	https://www.nature.com/articles/s41467-022-29301-9	NA	ChAdOx1 and BNT162b2	To study if heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1
19-Mar-22	Lancet	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study	Single-arm, open-label, phase 3B	Internationa	Bekker L.G., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00007-1/fulltext	NCT04838795	Ad26.COV2.S vaccine	Assessement of the effectiveness of a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the South African COVID-19 epidemic
28-Feb-22	eClinicalMedicine	A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19	RCT	USA	Rossignol et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00040-2/fulltext	NCT04486313	Nitazoxanide	Does treatment with nitazoxanide reduce the duration of symptoms of mild COVID-19?
01-Mar-22	eClinicalMedicine	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial	RCT	Thailand	Pitisuttithum et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00053-0/fulltext	NCT04764422	NDV-HXP-S vaccine	IS NDV-HXP-S vaccine safe?
01-April-22	The Lancet Microbe	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial	RCT	USA	Chiuppesi et al.	https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00027-1/fulltext	NCT046339466	COH04S1 vaccine (Ankara-based COVID-19 vaccine)	Tolerability and immunogenicity outcomes of vaccine
11-Mar-22	The Lancet Infectious Diseases	Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	RCT	USA	Welker et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00058-5/fulltext	NCT04317040	CD24Fc	Evaluate the safety and efficacy of CD24Fc in hospitalised adults with COVID-19 receiving oxygen support.
01-April-22	eClinicalMedicine	Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum	Observational retrospective study	UK	Kaura et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00074-8/fulltext#%20	NA	NA	Study compared the effectiveness of a single dose strategy of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines against SARS-CoV-2 infection across all age groups and over an extended follow-up period
26-Mar-22	The Lancet	Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study	Test-negative, case-control, and retrospective longitudinal study	Argentina	Rearte et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00011-3/fulltext#%20	NA	NA	To estimate vaccine effectiveness at reducing risk of SARS-CoV-2 infection and COVID-19 deaths in people older than 60 years.
01-April-22	eBioMedicine	Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months	Cross-sectional study	India	Medigeshi et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00122-0/fulltext	NA	NA	What is the ability of vaccine and natural infection induced antibodies to neutralise omicron variant
19-Mar-22	The Lancet	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study	CT	South Africa	Bekker et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00007-1/fulltext	NCT04838795,	Ad26.COV2.S vaccine (Johnson & Johnson)	effectiveness of a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers
01-April-22	eClinicalMedicine	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group	RCT	France	Hermine et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00092-X/fulltext#%20	NCT04476979	Tocilizumab + dexamethasone	Efficacy and safety of DEX+TCZ
29-Mar-22	The Lancet Rheumatology	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial	RCT	USA	Han et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00044-3/fulltext	NCT04362137.	Ruxolitinib	Whether treatment with the JAK1/JAK2 inhibitor ruxolitinib would be beneficial in patients with COVID-19 admitted to hospital
02-Apr-2022	The Lancet	Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India	RCT	India	Khobragade et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00151-9/fulltext	CTRI/2021/01/030416	ZyCoV-D, a DNA-based vaccine	Efficacy of ZyCoV-D vaccine
30-Mar-2020	NEJM	Early Outpatient Treatment for Covid-19 with Convalescent Plasma	RCT	USA	Sullivan et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2119657?query=featured_coronavirus	NCT04373460	Convalescent plasma	Efficacy and safety of convalescent plasma

12-Feb-22	Lancet	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	RECOVERY Collaborative Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00163-5/fulltext	NCT04381936	casirivimab and imdevimab	To evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19.
10-Feb-22	Nature Med	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial	RCT	USA	Pajon R., et al.	https://www.nature.com/articles/s41591-022-01679-5	NCT04470427	mRNA-1273 vaccine	Exploratory analyses to assess the impact of mRNA-1273 vaccination in the ongoing COVE trial on SARS-CoV-2 copy number and shedding, burden of disease and infection, and viral variants.
10-Feb-22	BMJ	Effectiveness of mRNA vaccines and waning of protection against SARS□CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study	cohort retrospective study	Italy	Fabiani M., et al.	https://www.bmj.com/content/376/bmj-2021-069052	NA	mRNA vaccines	To estimate the effectiveness of mRNA vaccines against SARS□CoV-2 infection and severe covid-19 at different time after vaccination (27 Dec 2020 to 7 Nov 2021).
09-Feb-22	NEJM	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S	RCT	USA	Sadoff J., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2117608	NCT04505722	Single-Dose Ad26.COV2.S	To report the final analysis of the double-blind phase of ENSEMBLE
08-Feb-22	Lancet Microbe	Safety and immunogenicity of two recombinant DNA COVID 19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults	vaccine trial	South Korea	Ahn J.Y., et al.	https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00358-X/fulltext	NCT044445389	DNA COVID 19 vaccines	To assess the safety and immunogenicity of two recombinant DNA vaccines for COVID-19: GX-19 containing plasmid DNA encoding the SARS-CoV-2 spike protein, and GX-19N containing plasmid DNA encoding the SARS-CoV-2 receptor-binding domain (RBD) foldon, nucleocapsid protein, and plasmid DNA encoding the spike protein.
03-Feb-22	Lancet Respir Med	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial	RCT	USA	Ely E.W., et al	https://linkinghub.elsevier.com/retrieve/pii/S2213260022000066	NCT04421027	baricitinib plus standard of care	To evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation.
9-Feb-22	The Lancet Respiratory Medicine	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial	RCT	Spain	Alemany et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00545-2/fulltext#%20	NCT04621123	convalescent plasma	assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19
16-Feb-22	NEJM	Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	RCT	Multinational	Hammond et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2118542?query=featured_coronavirus	NCT04960202	nirmatrelvir	Efficacy and safety of nirmatrelvir
26-Jan-22	NEJM	Homologous and Heterologous Covid-19 Booster Vaccinations	RCT	USA	Atmar et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2116414?query=featured_coronavirus	NCT04889209	Moderna, Johnson&Johnson, Pfizer vaccine	Safety, reactogenicity, and humoral immunogenicity of homologous and heterogenous booster vaccine
18-Feb-22	JAMA Intern. Med.	Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities The I-TECH Randomized Clinical Trial	RCT	Malaysia	Lim et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362	NCT04920942	ivermectin	Does adding ivermectin reduce the risk of severe disease in patients with COVID-19 and comorbidities?
31-Jan-22	Lancet Respir Med.	Safety and immunogenicity of a high□dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study	RCT	International	Izikson R., et al	https://www.nature.com/articles/s41586-022-04460-3	HREC 190/2020, 207/2020 and 209/2020 - University of Cape Town Human Research Ethics Committee	a third dose of the mRNA-1273 SARS-CoV-2 vaccine	To assess the safety and immunogenicity of concomitant administration of high-dose quadrivalent influenza vaccine (QIV-HD) and a mRNA-1273 vaccine booster dose in older adults. Ongoing, phase 2, multicentre, open-label, descriptive trial at six clinical research sites in the USA
27-Jan-22	Nature Med.	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	RCT	China	Li J., et al.	https://www.nature.com/articles/s41591-021-01677-z	NCT04892459	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccine	To evaluate the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial
27-Jan-22	Lancet	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double□blind, placebo-controlled, phase 3, randomised trial	RCT	International	Polizzotto M., et al.	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet	NCT04546581.	Anti-SARS-CoV-2 hIVIG	To evaluate the safety and clinical efficacy of anti-SARS-CoV-2 hIVIG in addition to standard of care including the antiviral remdesivir in individuals hospitalised with COVID-19 without end-organ failure
01-Jan-22	*EBioMedicine*	Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.	RCT	International	Vanhoutte R. et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00605-8/fulltext	NCT04498247	The measles vector-based SARS-CoV-2 vaccine candidate, V591	To evaluate the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate.

19-Jan-22	Nat Commun	A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.	RCT	India	Yogiraj R et al.	https://www.nature.com/articles/s41467-022-28064-7	CTRI/2020/05/025209	The convalescent plasma therapy	To evaluate all-cause mortality by day 30 of enrolment and immunological correlates of response to therapy of convalescent plasma.
15-Jan-22	*EBioMedicine*	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.	RCT	France	Odile L et al.	https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00604-6/fulltext	NCT04497298	The measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083	To evaluate the safety and immunogenicity of V591.
25-Jan-22	The Lancet Infectious Diseases	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study	RCT	USA/Honduras	Sridhar et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00764-7/fulltext	NCT04762680	CoV2 preS dTM spike recombinant protein vaccine	Safety and immunogenicity of an optimised formulation of CoV2 preS dTM adjuvanted with AS03 to inform progression to phase 3 clinical trial
3-Feb-22	The Lancet Respiratory Medicine	Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial	RCT	Argentina, Brazil, Mexico, and the USA	Wesley et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00006-6/fulltext	NCT04421027	baricitinib	Efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation
07-Jan-22	JAMA Netw Open	SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India	cohort study of HCWs	India	Malhotra S., et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787712	NA	Inactivated Whole Virion Vaccine BBV152	To assess the incidence density of reinfection among a cohort of HCWs and estimate the effectiveness of the inactivated whole virion vaccine BBV152 against reinfection in New Delhi, India - Vaccination with 0, 1, or 2 doses of BBV152.
07/12/2022	BMJ	Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial	RCT	Iran	Sadeghipour P., et al.	https://www.bmj.com/content/376/bmj-2021-068407	NCT04486508	Atorvastatin 20 mg orally once daily versus placebo, to be continued for 30 days from randomization irrespective of hospital discharge status.	To assess the effect of statin treatment versus placebo on clinical outcomes in Covid-19 patients admitted to intensive care unit (ICU)
10-Jan-22	Clin Microbiol Infect.	Efficacy of favipiravir in adults with mild COVID□19: a randomized, double□blind, multicenter, placebo-controlled trial clinical trial	RCT	Saudi Arabia	Bosaeed M., et al.	https://pubmed.ncbi.nlm.nih.gov/35026375/	NCT04464408	favipiravir	To evaluate whether favipiravir reduces the time to viral clearance as documented by negative SARS-CoV-2 RT-PCR in mild COVID-19 cases compared to placebo.
12-Jan-22	NEJM	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina	RWD - North Carolina Covid-19 Surveillance System and the Covid-19 Vaccine Management Systém	USA	Lin D.Y., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2117128	NA	BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson & Johnson–Janssen) vaccines	To estimate the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Johnson & Johnson–Janssen) vaccines in reducing the current risks of Covid-19, hospitalization, and death, as a function of time elapsed since vaccination (Dec 2020-Sept 2021).
12-Jan-22	NEJM	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines	RWD - Testing data were linked to the Emergency Care Data Set (ECDS)	UK	Andrews N., et al.	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines | NEJM	NA	ChAdOx1-S (ChAdOx1 nCoV-19) and BNT162b2 vaccine	To estimate ChAdOx1-S (ChAdOx1 nCoV-19) and BNT162b2 vaccine effectiveness against symptomatic Covid-19 and related hospitalization and death in England.
19-Jan-21	NEJM	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming	RCT	Netherlands	Sablerolles R.S.G., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2116747	NCT04927936	Boosters after Ad26.COV2.S Priming	To evaluate the immunogenicity and reactogenicity of a homologous or heterologous booster at day 28 in persons who have received an Ad26.COV2.S priming dose.
18-Jan-22	JAMA	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19 A Randomized Clinical Trial	RCT	USA/Spain/Brazil/Italy	Berger et al.	https://jamanetwork.com/journals/jama/fullarticle/2788141?guestAccessKey=bb7a7d14-3a15-498e-ba0a-7a6ec6fedb15&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=011822	NCT04505774	P2Y12 inhibitor	What is the effect of a P2Y12 inhibitor added to anticoagulant therapy on clinical outcomes in non–critically ill patients hospitalized for COVID-19?
24-Jan-22	JAMA	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19 The RECOVERY-RS Randomized Clinical Trial	RCT	UK	Perkins et al.	https://jamanetwork.com/journals/jama/fullarticle/2788505	ISRCTN16912075	CPAP, HFNO or conventional oxygen therapy	To determine whether either CPAP or HFNO, compared with conventional oxygen therapy, improves clinical outcomes in hospitalized patients with COVID-19–related acute hypoxemic respiratory failure.
21-Jan-22	JAMA	Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants	Test-negative case-control analysis	USA	Accorsi et al.	https://jamanetwork.com/journals/jama/fullarticle/2788485	NA	NA	To estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine and symptomatic SARS-CoV-2 infection, stratified by variant (Omicron and Delta).

14-Jan-22	JAMA	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection A Randomized Clinical Trial	RCT	USA/Romania/Moldova	O´Brien	https://jamanetwork.com/journals/jama/fullarticle/2788256	NCT04452318	casirivimab and imdevimab	To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19.
20-Jan-22	The Lancet	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial	RCT	Belgium, Brazil, Colombia, Philippines, and South Africa	Bravo et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00055-1/fulltext	NCT04672395, EudraCT 2020–004272–17	vaccine SCB-2019	Safety and efficacy of the COVID-19 vaccine SCB-2019
21-Jan-22	The Lancet	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	Phase 4, randomised study	Brazil	Clemens et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00094-0/fulltext	RBR–9nn3scw (Registro Brasileiro de Ensaios Clínicos)	Janssen, AstraZeneca, Pfizer-BioNTech, Sinovac vaccines	assessed whether a third dose of the homologous or a different vaccine could boost immune responses after two doses of Sinovac vaccine
24-Jan-22	The Lancet	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial	RCT	China	Chen et al.	https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00280-9/fulltext	ChiCTR2000039212	SARS-CoV-2 ARCoV mRNA vaccine	Assess the preliminary safety, tolerability, and immunogenicity of an mRNA vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain (RBD).
21-Dec-21	Ann Intern Med.	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System	RWD trial	USA	Ioannou, G.N, et al.	https://www.acpjournals.org/doi/10.7326/M21-3256	U.S. Department of Veterans Affairs health care system -	Moderna or Pfizer–BioNTech COVID-19 vaccine	To determine the effectiveness of messenger RNA COVID-19 vaccines in racially and ethnically diverse, elderly populations with high comorbidity burden.
20-Dec-21	Lancet	Two-dose ChAdOx1 nCoV19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil	Cohorts of adults who received two doses of ChAdOx1 nCoV-19	Brazil/UK	Katikireddi S.V., et al.	https://linkinghub.elsevier.com/retrieve/pii/S0140673621027549	CONEP approval number 4.921.308 (Brazil), National Research Ethics Service Committee, Southeast Scotland 02 (reference number: 12/SS/0201 (UK)	ChAdOx1 nCoV-19 vaccine	To investigate the association between time since two doses of ChAdOx1 nCoV-19 vaccine and risk of severe COVID-19 outcomes in Scotland (where delta was dominant), with comparative analyses in Brazil (where delta was uncommon).
16-Dec-21	BMJ	SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study	RWD trial - 12 years or older	Denmark	Husby A., et al.	https://www.bmj.com/content/375/bmj-2021-068665	NA	mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)	To investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis.
16-Dec-21	Lancet Respir Med.	Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial	RCT - 2 phase	UK	Fisher B.A, et al	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext	ISRCTN 40580903	namilumab and infliximab	To assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise agents for phase 3 trials.
15-Dec-21	NEJM	Efficacy and Safety of NVXCoV2373 in Adults in the United States and Mexico	RCT - 3 phase	USA	Dunkle, L.M, et al.	https://www.nejm.org/doi/10.1056/NEJMoa2116185	NCT04611802	NVX-CoV2373 - adjuvanted, recombinant spike protein nanoparticle vaccine.	To prove the clinical efficacy for the prevention of COVID19 in phase 2b–3 trials in the UK and South Africa. Primary objective vaccine efficacy against RT PCR confimed cases occurring at least 7 days after the second dose. Vaccine efficacy against moderate-to-severe disease and against different variants was also assessed.
07-Dec-21	Science Transl Med.	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV2 experienced individuals.	Prospective cohort study	USA	Samanovic M.I., et al.	https://www.science.org/doi/10.1126/scitranslmed.abi8961	NYU Institutional Review Board (protocols 18-02035 and 18-02037)	two-dose BNT162b2 mRNA vaccine	To evaluate longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19.
23-Dec-21	The Lancet Infectious Diseases	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial	RCT	Multinational (USA, Denmark, Poland, Switzerland)	ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext#%20	NCT04501978	sotrovimab and BRII-196 plus BRII-198	Assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab and BRII-196 plus BRII-198) for adults admitted to hospital for COVID-19
23-Dec-21	The Lancet	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial	RCT	Multinational (Argentina, Chile, Mexico, Pakistan, Russia)	Halperin et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext#%20	NCT04526990	Ad5-nCoV vaccine	efficacy and safety of Ad5-nCoV vaccine
10-Nov-21	Intensive Care Medicine	Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial	Secondary analysis of RCT	Denmark	Granholm et al.	https://link.springer.com/article/10.1007%2Fs00134-021-06573-1	EudraCT, 2020-003363-25, NCT04509973	dexamethasone	Analysed outcome data of RCT using Bayesian models with various sensitivity to assess the differences between dexamethasone 12 vs. 6 mg in COVID patients
Jan-22	International Journal of Infectious Diseases	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial	RCT	Japan	Asano et al.	https://www.sciencedirect.com/science/article/pii/S1201971221008183?via%3Dihub	NCT04568031	ChAdOx1 nCoV-19 vaccine	Immunigenicity and safety of ChAdOx1 nCoV-19 vaccine in Japanese adults
23-Nov-21	The Lancet Infectious Diseases	Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study	Case-control study	India	Devashish et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00674-5/fulltext#	NA	NA	The effectiveness of BBV152 against symptomatic RT-PCR-confirmed SARS-CoV-2 infection

25-Nov-21	The Lancet Infectious Diseases	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses	Case-control study	India	Thiruvengadam et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00680-0/fulltext#%20	NA	NA	Effectiveness of the ChAdOx1 nCoV-19 vaccine, predominantly against the delta (B.1.617.2) variant, in addition to the cellular immune response to vaccination
1-Dec-21	The Lancet Respiratory Medicine	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial	RCT	Multinational	Temesgen et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext	NCT04351152	Lenzilumab	To assess efficacy and safety of lenzilumab in treating COVID-19 beyond available treatments
2-Dec-21	The Lancet	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	RCT	UK	Munro et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext	ISRCTN 73765130	Covid vaccines	Reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 or BNT162b2
7-Dec-21	The Lancet Infectious Diseases	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials	RCT	China	Zeng et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00681-2/fulltext#%20	NCT04352608 and NCT04383574	CoronaVac vaccine	Immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18 years and older
08-Dec-21	NEJM	BNT162b2 Vaccine Booster and Mortality Due to Covid-19	Real world data for all members of Clalit Health Services, CHS data repositories	Israel	Arbel R., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2115624	NA	BNT162b2 booster	To gather evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 over the Delta wave
08-Dec-21	NEJM	Protection against Covid□19 by BNT162b2 Booster across Age Groups	Real world data, Israel Ministry of Health database	Israel	Bar-On Y.M., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2115926	NA	BNT162b2 Booster	To gather evidence on protection against Covid-19 by BNT162b2 booster to persons in younger age groups
03-Dec-21	JAMA	Immunogenicity of Extended mRNA SARS□CoV-2 Vaccine Dosing Intervals	cohort study - paramedics	Canada	Grunau B., et al.	https://jamanetwork.com/journals/jama/fullarticle/2786992	NA	Extended mRNA SARS□CoV-2 Vaccine Dosing Intervals	To investigate the immunogenicity of extended mRNA vaccine dosing intervals
25-Oct-21	BMJ	Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study	Test negative design study,	Israel	Israel A., et al	https://www.bmj.com/content/375/bmj-2021-067873	Electronic health records of a large state mandated healthcare organisation, Israel.	Pfizer-BioNTech BNT162b2 mRNA vaccine	To determine whether time elapsed since the second injection of the Pfizer-BioNTech BNT162b2 mRNA vaccine was significantly associated with the risk of covid-19 infection after vaccination in people who received two vaccine injections.
23-Oct-21	Science	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial	RCT	USA	Gilbert P.B., et al.	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial (science.org)	NCT04470427	mRNA-1273 COVID-19 vaccine	To evaluate the efficacy of mRNA-1273 COVID-19 vaccine
23-Oct-21	Nature	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity	phase I vaccine trial	Germany	Heitmann J.S., et al.	https://www.nature.com/articles/s41586-021-04232-5	NCT04954469	CoVac-1	Phase I open-label trial on 36 participants aged 18 to 80 years, who received one single subcutaneous CoVac-1 vaccination. Primary endpoint: safety analysed until day 56. Main secondary endpoint: immunogenicity in terms of CoVac-1-induced T-cell response, analysed as until day 28 and in the follow-up until month 3.
23-Oct-21	Lancet Infect Dis.	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo□controlled, phase 2b/3 trial	RCT	International	Kremsner P. G., et al	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00677-0/fulltext	NCT04652102, and EudraCT, 2020–003998–22,	CVnCoV SARS-CoV-2 mRNA vaccine	To analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate.
19-Oct-21	Clin Infect Dis.	Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial	RCT	Malaysia	Chuan Huan C., et al	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab962/6432025?searchresult=1	NCT04818320	favipiravir	To determine its effect in preventing disease progression from non-hypoxia to hypoxia among high risk COVID-19 patients.
17-Nov-21	The Lancet Rheumatology	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial	RCT	France	The CORIMUNO-19 Collaborative group	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00315-5/fulltext	NCT04324073	sarilumab	Effect of sarilumab in moderate to severe COVID-19 pneumonia
17-Nov-21	The Lancet Respiratory Medicine	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial	RCT	UK	Toback et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00409-4/fulltext	NCT04583995	NVX-CoV2373 vaccine and influenza vaccines	Safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines
17-Nov-21	The Lancet	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	RECOVERY Collaborative Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01825-0/fulltext	NCT04381936	Efficacy and safety of aspirin in patients admitted to hospital with COVID-19	Efficacy and safety of aspirin in patients admitted to hospital with COVID-19
23-Nov-21	Scientific reports	Comparing the clinical efficacy of COVID 19 vaccines: a systematic review and network meta analysis	systematic review and meta-analysis	Israel	Rotshild et al.	https://pubmed.ncbi.nlm.nih.gov/34815503/	NA	COVID-19 vaccines	Compare the efficacy of COVID-19 vaccines to prevent symptomatic and severe disease in adults and prevent symptomatic COVID-19 among eldery

23-Nov-21	American Journal of Respiratory and Critical Care Medicine	Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial	RCT	Denmark	Johansson et al.	https://www.atsjournals.org/doi/10.1164/rccm.202108-1855OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	NCT 04420741; EudraCT Identifier: 2020-001296-33	Prostacyclin	Effect of prostacyclin infusion in mechanically ventilated SARSCoV-2 infected patients with severe endotheliopathy
22-Nov-21	JAMA	Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19 A Randomized Clinical Trial	RCT	USA	Clemency et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786012	NCT04377711	Ciclesonide	Efficacy of the inhaled steroid ciclesonide in reducing the time to alleviation of all COVID-19–related symptoms among nonhospitalized participants with symptomatic COVID-19 infection
Dec-21	E Clinical Medicine	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial	RCT	Switzerland	Labhardt et al.	https://pubmed.ncbi.nlm.nih.gov/34778734/	NCT04364022	lopinavir/ritonavir	Is lopinavir/ritonavir effective in post-exposure prophylaxis?
28-Oct-21	NEJM	Early Treatment for Covid□19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab	RCT	USA	Gupta A., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2107934	NCT04545060. opens in new tab	Sotrovimab	To evaluate the safety and efficacy of sotrovimab. If Sotrovimab can reduce the risk of disease progression in high-risk patients with mild-to-moderate Covid-19.
26-Oct-21	Science Transl Med.	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults	Phase I vaccine trial	Italy	Lanini S., et al.	https://www.science.org/doi/10.1126/scitranslmed.abj1996	NCT04528641	GRAd□COV2 vaccine	To describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 spike protein, named GRAd-COV2; and asses the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group
25-Oct-21	Nature Medicine	Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	self-controlled case series study	UK	Patone M et al.	https://www.nature.com/articles/s41591-021-01556-7	NA	ChAdOx1nCoV-19 or BNT162b2	To investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280).
14-Sep-21	Science	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells	samples from the phase 1 mRNA-1273 study	USA	Mateus J. et al.	https://www.science.org/doi/10.1126/science.abj9853	NCT04283461	Moderna messenger RNA (mRNA)–1273 vaccine	To examine vaccine-specific CD4+ T cell, CD8+ T cell, binding antibody, and neutralizing antibody responses to the 25-mg Moderna messenger RNA (mRNA)–1273 vaccine over the course of 7 months after immunization.
21-Oct-21	JAMA	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial	RCT	Denmark	Perner A., et al.	https://jamanetwork.com/journals/jama/fullarticle/2785529	NCT04509973	12 mg vs 6 mg of Dexamethasone	To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia
18-Oct-21	Lancet Respir Med	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	RECOVERY Collaborative Group	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext	NCT04381936	colchicine	To evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19
16-Oct-21	Cell	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine	cohort study	Thailand	Payne R. P., et al.	https://www.cell.com/cell/pdf/S0092-8674(21)01221-6.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421012216%3Fshowall%3Dtrue	NA	BNT162b2 mRNA vaccine	To demonstrate the impact of extended dosing intervals on BNT162b2 mRNA vaccine effectiveness against infection.
15-Oct-21	NEJM	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines	(#2021P000344) and the parent biorepository study (#2020P000361)	USA	Collier A.Y., et al.	https://www.nejm.org/doi/10.1056/NEJMc2115596	(#2021P000344) and the parent biorepository study (#2020P000361)	two-dose BNT162b2 vaccine (n=31), the two□dose mRNA-1273 vaccine	To report comparative kinetics of humoral and cellular immune responses elicited by the two-dose BNT162b2 vaccine (n=31), the two□dose mRNA-1273 vaccine (n=22), and the one-dose Ad26.COV2.S vaccine (n=8) up to 8 months after vaccination.
4-Oct-21	JAMA	Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial	RCT	UK	Estcourt et al.	https://jamanetwork.com/journals/jama/fullarticle/2784914?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=110221	NCT02735707	Convalescent plasma	To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19
27-Oct-21	Lancet Glob Health	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial	RCT	Brazil	Reis et al.	https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext	NCT04727424	Fluvoxamine	Efficacy of fluvoxamine versus placebo in preventing hospitalisation

29-Oct-21	The Lancet Respiratory Medicine	Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial	RCT	Belgium	Declercq et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00377-5/fulltext	NCT04330638, EudraCT 2020-001500-41	anti-IL1 and anti-IL6 drugs (anakinra, siltuximab, tocilizumab)	Whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome
29-Oct-21	The Lancet	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	Observational study	Israel	Barda et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext	NA	NA	evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes
11-Nov-21	The Lancet Respiratory Medicine	Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial	RCT	France	Mazeraud et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00440-9/fulltext	NCT04350580	Immunoglobulins	whether intravenous immunoglobulins (IVIG) could improve outcomes by reducing inflammation-mediated lung injury
11-Nov-21	The Lancet	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial	RCT	UK	Lazarus et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext	ISRCTN14391248	ChAdOx1 or BNT162b2 vaccine	Safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine
11-Nov-21	The Lancet	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial	RCT	India	Ella et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext	, NCT04641481	BBV152	clinical efficacy of BBV152 vaccine against SARS-CoV-2
24-Sep-21	Clinical Trial	A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia	RCT	Indonesia	Fadlyana et al.	https://pubmed.ncbi.nlm.nih.gov/34620531/	NCT04508075	Sinovac Vaccine	Efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine
1-Oct-21	Plos Medicine	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial	RCT	USA	Formica et al.	https://pubmed.ncbi.nlm.nih.gov/34597298/	NCT04368988	NVX-CoV2373 vaccine	Identification of dosing regimen of NVX-CoV2373 vaccine
05-Oct-21	Nature Commun.	Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil	post hoc analysis of phase III vaccine trial	Brazil/UK	Costa Clemens S.A., et al.	https://www.nature.com/articles/s41467-021-25982-w	ISRCTN89951424 - post hoc analysis	ChAdOx1 nCoV19 (AZD1222) vaccine	To investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil.
30-Sep-21	Nature Medicine	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	RCT	USA	Shroff R.T. et al.	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors | Nature Medicine	NCT04936997	BNT162b2 mRNA vaccine	To compare the immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors (n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer (n = 50).
30-Sep-21	Science Transl Med	AZD1222/ChAdOx1 nCoV19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire	RCT	USA	Swanson P.A., et al.	https://www.science.org/doi/10.1126/scitranslmed.abj7211	NCT04400838	AZD1222 (ChAdOx1 nCoV-19) vaccine	To characterize CD4+ and CD8+ T cell responses induced by AZD1222 (ChAdOx1 nCoV-19) vaccination in peripheral blood mononuclear cells (PBMCs) from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial.
13-Oct-21	preprint Research Square	Early treatment with inhaled GM-CSF improves oxygenation and anti-viral immunity in COVID-19 induced lung injury – a randomized clinical trial	RCT	Belgium	Lambrecht c et al.	https://assets.researchsquare.com/files/rs-959220/v1_covered.pdf?c=1634226283	NCT04326920	inhalation of rhu-GM-CSF (sargramostim, Leukine®)	To evaluate the safety and efficacy rhu-GM-CSF (sargramostim, Leukine®) of 5 days of inhalation of rhu-GM-CSF (sargramostim, Leukine®) in non-ventilated patients with COVID-19 and hypoxemic respiratory failure identified by PaO2/FiO2 ratio < 350mmHg.
13-Oct-21	Radiotherapy and Oncology	Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen-Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone and/or Remdesevir	RCT	USA	Hess CB et al.	Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen-Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone and/or Remdesevir - ScienceDirect	NCT04366791	Low-dose radiotherapy	To evaluate if the addition of LD-RT to standard drug treatments leads to reduction of biomarkers of inflammation and cardiac injury in COVID-19 patients and leads to reduction of intubation.
13-Oct-2021	The Lancet Respiratory Medicine	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan	RCT	Taiwan	Szu-Min Hsieh	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext	NCT04695652	MVC-COV1901 vaccine	Safety, tolerability, and immunogenicity MVC-COV1901 vaccine
7-Oct-2021	NEJM	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	RCT	USA	Dougan et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2102685	NCT04427501	bamlanivimab plus etesevimab	The primary outcome was the overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29.

29-Sep-21	NEJM	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19	RCT III phase	USA	Weinreich D.M., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2108163	NCT04425629	REGEN-COV (casirivimab/imdevimab)	To evaluate the efficacy and safety of REGEN-COV (casirivimab/imdevimab), at 2400-mg or 1200-mg doses, on outpatients with Covid-19 and risk factors for severe disease. End points: hospitalization or death and the time to resolution of symptoms at day 29.
29-Sep-21	NEJM	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	RCT III phase	International	Falsey A.R., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2105290	NCT04516746	AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	To evaluate the safety, efficacy and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe Covid-19 ≥15 days after the second dose in adults, including older adults, in the USA, Chile, and Peru.
22-Sep-21	Clin Infect Dis.	Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo□controlled, phase 2b tria	vaccine II phase	China	Zhu F., et al	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab845/6374123	NCT04566770	to assess safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. 3 doses (low-dose vaccine, middle-dose vaccine or placebo) given intramuscularly 56 days apart.	to assess safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. - 3 doses (low-dose vaccine, middle-dose vaccine or placebo) given intramuscularly 56 days apart.
22-Sep-21	NEJM	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase	RCT III phase	USA	Sahly H.M., et al	https://www.nejm.org/doi/10.1056/NEJMoa2113017	NCT04470427	mRNA-1273 SARS-CoV-2 Vaccine	To evaluate the efficacy and safety data from the blinded phase of the phase 3 trial of mRNA-1273 Moderna vaccine are reported.
15-Sep-21	NEJM	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3	RCT 1-2-3 pivotal phase	USA	Falsey A.R., et al	https://www.nejm.org/doi/10.1056/NEJMc2113468	NCT04368728	BNT162b2 Vaccine Dose 3	To evaluate the safety and immunogenicity of a booster dose of BNT162b2 administered 7-9 months after the primary two-dose series
15-Sep-21	Clin Infect Dis.	Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19	RCT	USA	Ananworanich J., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab813/6370549	NCT04504032	rivaroxaban	To investigate whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor would reduce COVID-19 progression.
19-Sep-21	Clin Infect Dis.	Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile	RCT III phase	Chile	Bueno S.M., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab823/6372423	NCT04651790	Inactivated SARS-CoV-2 Vaccine	To evaluate the safety and immunogenicity of inactivated SARS-CoV-2 vaccine CoronaVac
October-2021	Pharm Res & Prosp	Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8	RCT	Germany & USA	Port et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377444/	NCT03676322	enpatoran	Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of enpatoran
October-2021	International Immunopharmacology	Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials	metaanalysis of RCT	Taiwan	Chen et al.	https://pubmed.ncbi.nlm.nih.gov/34343937/	NA	JAK inhibitors (baricritinib, tofacitinib, ruxolitinib)	Clinical efficacy and safety of Janus kinase (JAK) inhibitors for COVID-19 patients
October-2021	International Immunopharmacology	An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial	RCT	Iran	Darazam et al.	https://pubmed.ncbi.nlm.nih.gov/34224994/	NCT04521400	IFN-β 1a	The effectiveness of high-dose IFN-β 1a compared to low dose IFN-β 1a in severe COVID-19 cases.
10-Aug-21	Lancet	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	RCT	UK	Yu L.M., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01744-X/fulltext	ISRCTN86534580	Inhaled budesonide	To establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community.
11-Aug-21	NEJM	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients	RCT	Canada	Hall V.G., et al.	https://www.nejm.org/doi/10.1056/NEJMc2111462	NCT04885907. opens in new tab	mRNA-1273 Vaccine	Double-blind, randomized, controlled trial of a third dose of mRNA□1273 vaccine (Moderna) as compared with placebo in transplant recipients.
11-Aug-21	NEJM	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents	RCT	USA	Ali K., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2109522	NCT04649151	mRNA-1273 vaccine	To test safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents.
18-Aug-21	NEJM	Early Convalescent Plasma for High-Risk Outpatients with Covid-19	RCT	USA	Korley F.K., et al	Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM	NCT04355767. opens in new tab.	Convalescent plasma	Randomized, multicenter, single-blind trial, on COVID-19 patients treated in emergency departments receiving either one unit of convalescent plasma with a high titer of antibodies against SARS□CoV-2 or placeb
19-Aug-21	Blood Advances	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma	RCT	Israel	Perry C., et al	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma | Blood Advances | American Society of Hematology (ashpublications.org)	NCT04746092	SARS-CoV-2 vaccine	To investigate the humoral response to SARS-CoV-2 vaccine in patients with B-NHL and looked at factors affecting the response rate to the vaccine

23-Aug-21	Clin Microbiol Infect	Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1	RCT	Israel	Levy I., et al	https://linkinghub.elsevier.com/retrieve/pii/S1198743X21004237	NA	Pfizer-BioNTech BNT162b2 mRNA	To assess the immunogenicity and safety the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with HIV-1 (PLWH) .
1-Sep-21	Clin Infect Dis	Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial	RCT	USA	Strich J.R., et al	Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial | Clinical Infectious Diseases | Oxford Academic (oup.com)	NCT04579393	Fostamatinib	To evaluate if Fostamatinib will ameliorate Fc activation and attenuate harmful effects of the anti-COVID-19 immune response.
1-Sep-21	Lancet	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)	RCT	USA	Flaxman A., et al.	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet	NCT04324606, NCT04400838	ChAdOx1 nCoV-19	To assess the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose.
1-Sep-21	Lancet Respir Med	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo‐controlled phase 3 trial	RCT	USA	Marconi V. C., et	Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine	NCT04421027	Baricitinib	To evaluate the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19.
3-Sep-21	Nature Med.	Early treatment of COVID‐19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double‐blind, randomized controlled phase 3 trial	RCT	Greece	Kyriazopoulou, E.,	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial | Nature Medicine	NCT04680949	Anakinra	To evaluate if and early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure
7-Sep-21	Lancet Rheumatol.	Humoral and cellular responses to mRNA vaccines against SARS‐CoV-2 in patients with a history of CD20 B-cell‐depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	RCT	Switzerland	Moor M.B., et al.	Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study - The Lancet Rheumatology	NCT04877496.	SARS-CoV-2 mRNA	To investigate humoral and cell-mediated immune responses to SARS-CoV-2 mRNA-based vaccines in patients receiving CD20-targeted B-cell-depleting agents (rituximab or ocrelizumab).
14-Sep-21	Lancet Infect Dis	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	RCT	France	Ader F., et al	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00485-0/fulltext	NCT04315948	Remdesivir	To evaluate the clinical efficacy of remdesivir plus standard of care (SoC) compared with SoC alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support.
15-Sep-21	Nature Med.	Safety and immunogenicity of SARS‐CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	RCT	USA	Choi A., et al.	https://www.nature.com/articles/s41591-021-01527-y	NCT04405076)	single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211.	exploratory interim analysis to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. Participants: received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier. Analysis includes preliminary descriptive results only of four booster groups (n = 20 per group).

15-Sep-21	NEJM	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	RCT	USA	Thomas S.J. et al.	https://www.nejm.org/doi/10.1056/NEJMoa2110345	NCT04368728	BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
31-Jul-21	Medrxiv	Phase 1 Safety and Pharmacokinetics Studies of BRII-196 and BRII-198, SARS-CoV-2 Spike-Targeting Monoclonal Antibodies	Phase 1 RCT	China	Zhang et al.	https://www.medrxiv.org/content/10.1101/2021.07.21.21260964v2	NCT04479631, NCT04479644	BRII-196 and BRII-198 anti SARS-CoV-2 spike monoclonal antibodies	Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198
8-Aug-21	Medrxiv	Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial	RCT	Taiwan	Szu-Min et al.	https://www.medrxiv.org/content/10.1101/2021.08.05.21261532v1	NCT04695652	MVC-COV1901 vaccine	safety and immunogenicity of the COVID-19 vaccine MVC-COV1901
28-Jul-21	Medrxiv	Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy	RCT	Netherlands	Rozeen et al.	https://www.medrxiv.org/content/10.1101/2021.07.27.21261116v1	Trial NL9275	mRNA-1273 vaccine	Tolerability and safety of mRNA-1273 vaccine
14-Jul-21	NEJM	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	RCT Phase 3	USA	Dougan M., et a	https://www.nejm.org/doi/10.1056/NEJMoa2102685	NCT04427501	Bamlanivimab plus Etesevimab	Primary outcome: overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29.
14-Jul-21	NEJM	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination	Correspondance	Netherland	Barouch D.H., et al.	https://www.nejm.org/doi/10.1056/NEJMc2108829	NCT04436276.	Ad26.COV2.S vaccine	To describe the 8-month durability of humoral and cellular immune responses in 20 participants who received the Ad26.COV2.S vaccine in one or two doses (either 5×1010 viral particles or 1011 viral particles) and in 5 participants who received placebo.
14-Jul-21	Nature Medicine	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	Brief Communication	Germany	Barros-Martins J et al.	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine	NA	ChAd-primed and 3 weeks after booster with ChAd or BioNTech/Pfizer's BNT162b2	To monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd or BioNTech/Pfizer's BNT162b2.
12-Jul-21	JAMA	Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women	cohort study	Israel	Goldshtein I., et al	https://jamanetwork.com/journals/jama/fullarticle/2782047	NA	BNT162b2 mRNA vaccine	To assess the association between receipt of BNT162b2 mRNA vaccine and risk of SARS-CoV-2 infection among pregnant women.
08-Jul-21	Lancet	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	RCT	Turkey	Tanriover M.D., et al	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext	NCT04582344	Inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac	Interim efficacy and safety results of a phase 3 clinical trial of CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, in Turkey
30-Jun-21	NEJM	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine	RCT	UK	Heath P.T., el al.	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM	2020-004123-16	NVX-CoV2373 vaccine (Novavax) is a recombinant nanoparticle vaccine against SARS-CoV-2 that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvan	To assess the Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
20-Jul-21	JAMA	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19	RCT	International	Caricchio R. et al.	https://jamanetwork.com/journals/jama/article-abstract/2782185?resultClick=1	NCT04362813	canakinumab, an anti–interleukin-1β antibody	Is the anti–interleukin-1β antibody canakinumab effective to treat patients hospitalized with COVID-19 and hyperinflammation?
16-Jul-21	JAMA	Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection	RCT	USA	Oldenburg CE et al.	https://jamanetwork.com/journals/jama/fullarticle/2782166?resultClick=1	NCT04332107	Azithromycin	To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14
6-Jul-21	JAMA	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19	Meta-analysis	International	The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group	https://jamanetwork.com/journals/jama/fullarticle/2781880?resultClick=1	NA	IL-6 antagonists	Is administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19?
2-Jul-21	The Lancet Respiratory Medicine	BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers	RCT	Israel	Lustig et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00220-4/fulltext	NA	Comirnaty Vaccine	Early antibody responses and antibody kinetics after each vaccine dose in health-care workers of different ages and sexes, and with different comorbidities
9-Jul-21	The Lancet Respiratory Medicine	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	RCT	UK	Hinks et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00263-0/fulltext	NCT04381962	azithromycin	Whether azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19

2-Jul-21	BMC Infectious Diseases	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial	RCT	Argentina	Vallejos et al.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5	NCT04529525	Ivermectin	Whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19
15-Jul-21	NEJM	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents	RCT	USA	Frenck et al.	https://www.nejm.org/doi/10.1056/NEJMoa2107456?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	NCT04368728	BNT162b2	Safety and efficacy of BNT162b2 vaccine against COVID-19
28-Jun-21	The Lancet Infectious Diseases	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	RCT	China	Han et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext	NCT04551547	CoronaVac vaccine	Assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac in children and adolescents aged 3–17 years
19-Jun-21	International Journal of Infectious Diseases	Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial	Bayesian re-analysis	UK	Hamilton FW et al.	https://www.sciencedirect.com/science/article/pii/S1201971221005233?via%3Dihub	NCT04381936	convalescent plasma	To re-analyse of the data using Bayesian methods suggests there is a real possibility of benefit of convalescent plasma
16-Jun-21	NEJM	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia	RCT	Brazil	Guimarães P.O.,et al	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM	NCT04469114	Tofacitinib	To evaluate efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with Covid-19 pneumonia.
9-Jun-21	Nature	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans	Re-using the samples collected from RCT	International	Alter G., et al	https://www.nature.com/articles/s41586-021-03681-2	NCT04436276	Ad26.COV2.S vaccine	Study of the humoral and cellular immune responses induced by Ad26.COV2.S against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants (Population enroled at COV1001 phase 1/2 clinical trial)
12-Jun-21	International Immunopharmacology	Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial	RCT	Iran	HosseinKasiri	Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial - ScienceDirect	IRCT20190804044429N6	Mometasone furoate nasal spray	To evaluate the usage of mometasone furoate nasal spray in the recovery of patients with severe microsmia or anosmia induced by COVID-19.
4-jun-2021	Lancet	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	RCT	Brazil	Lopes et al	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901203-4	NCT04394377	rivaroxaban, enoxaparin, heparin	to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation
17-Jun-21	The Lancet Respiratory Medicine	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial	RCT	Netherlands	Aman et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00237-X/fulltext	EudraCT 2020–001236–10	imatinib	Does imatinib reduce the time to discontinuation of ventilation and supplemental oxygen in patients with COVID-19?
28-Jun-21	The Lancet Infectious Diseases	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	RCT	China	Han et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext	NCT04551547	CoronaVac vaccine	To assess the safety, tolerability, and immunogenicity of COVID-19 vaccine CoronaVac in children and adolescents aged 3–17 years
25-Jun-21	The Lancet	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	RCT	Spain	Borobia et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01420-3/fulltext	NCT04860739, EudraCT 2021-001978-37	Comirnaty and AstraZeneca vaccine	To assess the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).
9-jun-2021	MedRxiv	Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a 2 randomised, double-blinded, phase 2/3, placebo-controlled trial	RCT	Mexico	Fragoso-Saavedra et al	https://www.medrxiv.org/content/10.1101/2021.04.28.21255834v2.full.pdf	NCT04343963	pyridostigmine	to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19
8-jun-2021	MedRxiv	Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)	RCT	India	Singh et al	https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1.full.pdf	The trial was registered at the Clinical Trial Registry of India (CTRI/2020/06/025575)	hydroxychloroquine, lopinavir-ritonavir, ribavirin	To evaluate the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19
16-jun-2022	MedRxiv	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: REGEN-COV for COVID-19	RCT	UK	RECOVERY Group	https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1.full.pdf	NCT04381936	REGEN-COV (casirivimab and imdevimab)	To evaluate the efficacy and safety of REGEN-COV (a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the 26 SARS-CoV-2 spike protein) in patients admitted to hospital with COVID-19
8-jun-2021	MedRxiv	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: Aspirin for COVID-19	RCT	UK	RECOVERY Group	https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1	NCT04381936	acetylsalicylic acid	To evaluate the effects of aspirin in patients hospitalised with COVID-19

27-May-2021	NEJM	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents	multinational, placebo-controlled, observer-blinded trial	USA	Frenck RW et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2107456?articleTools=true	NCT04368728	BNT162b2 or placebo	To assess the safety (reactogenicity and ad- verse events) and efficacy against confirmed Covid-19 ≥7 days after dose 2 in the 12-to-15-year-old cohort
13-May-2021	NEJM	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	multicenter, placebo-controlled, phase 1–2a trial	The Netherlands	Sadoff J et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034201?articleTools=true	NCT04436276	Ad26.COV2.S vaccine (J&J) at a dose of 5×1010 viral particles (low dose) or 1×1011 viral particles (high dose)	The safety and immunogenicity profiles of Ad26.COV2
21-May-2021	MedRxiv	Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial	single-blinded parallel-randomized controlled trial	Egypt	Elgohary MA et al	https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1.full.pdf	NCT04530422	Sofosbuvir/ledipasvir (S.L. group) vs control group (Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group))	To investigate the efficacy of Sofosbuvir/ledipasvir in the treatment of COVID-19 compared to the standard of care
27-May-21	Lancet Respir Med	Colchicine for community□treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	RCT	Canada	Tardif J., et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00222-8/fulltext	NCT04322682	Colchicine	To investigate the effect of colchicine (oral anti-inflammatory) on the composite of COVID-19-related death or hospital admission.
26-May-21	JAMA	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial	RCT	United Arab Emirates and Bahrain a	Kaabi NA. et al.	https://jamanetwork.com/journals/jama/fullarticle/2780562	NCT04510207	inactivated SARS-CoV-2 vaccines	To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines
27-May-21	Nature	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans	vaccine trial	Germany	Sahin U., et al	https://www.nature.com/articles/s41586-021-03653-6	NCT04380701	BNT162b2 vaccine	To extend the previous phase 1/2 trial report and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age).
25-May-21	Clin Microbiol Infect	An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 (DisCoVeRy)	RCT	France	Ader F., et al	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext	NCT04315948	lopinavir/ritonavir, lopinavir/ritonavir-IFN-ß-1a and hydroxychloroquine	To evaluate clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support.
3-Jun-21	JAMA	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities A Randomized Clinical Trial	RCT	USA	Cohen M., et al.	https://jamanetwork.com/journals/jama/fullarticle/2780870	NCT04497987	bamlanivimab	To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.
22-May-21	NEJM	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	RCT	USA	Rosas et al.	https://www.nejm.org/doi/10.1056/NEJMoa2028700	NCT04320615	Tocilizumab	Efficacy of tocilizumab in patients with severe COVID-19 infection
26-May-21	Viruses	Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon	RCT	Lebanon	Samaha AA. et al.	https://www.mdpi.com/1999-4915/13/6/989/htm	NA	Ivermectin	To determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon
5-May-2021	NEJM	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	Phase 2a-b RCT	South Africa	Shinde et al (2019nCoV-501 Study Group)	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103055?articleTools=true	NCT04533399	NVX-CoV2373 vaccine (Novavax)	To assess the efficacy of a two-dose regimen of NVX-CoV2373 nanoparticle vaccine in preventing symptomatic Covid-19 during predominant transmission of the B.1.351 variant in South Africa
13-May-2021	NEJM	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	Phase 1–2a trial	The Netherlands	Sadoff et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034201?articleTools=true	NCT04436276	Ad26.COV2.S vaccine (janssen vaccine) at a dose of 5×1010 viral particles (low dose) or 1×1011 viral particles (high dose) per milliliter or placebo in a single-dose or two-dose schedule.	Interim results of a multicenter, randomized, double-blind, placebo-controlled, phase 1–2a clin- ical trial (COV1001) involving healthy adults in two age cohorts to evaluate the safety, reactoge- nicity, and immunogenicity of Ad26.COV2.S
4-May-2021	BMC Infectious Diseases	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients	Prospective, randomized, controlled, single-blind phase 3 study	Turkey	Okumus et al	https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-021-06104-9.pdf	NCT04646109	Ivermectin 200 mcg/kg/day for 5 days in the form of a solution prepared for enteral use added to the reference treatment protocol: hydroxychloroquine + favipiravir + azithromycin Patients in the control group were given only reference treatment with 3 other drugs without ivermectin	To investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation.
5-May-2021	MedRxiv	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study.	Phase 1b/2a RCT (AGILE)	UK	Khoo et al	https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1.full.pdf	NCT04746183	300mg, 600mg and 800mg doses of molnupiravir orally, twice daily for 5 days or control	To determine the safety and tolerability of multiple ascending doses of molnupiravir in participants with symptomatic COVID-19 to recommend a dose for phase II.
7-May-2021	MedRxiv	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure	Phase 2 CT	USA	Mammen P et al	https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1.full.pdf	NCT04642638	DNA vaccine (INO-4800)	To assess the safety and immunogenicity of a DNA vaccine (INO-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of exposure

18-May-21	Nature Med.	Phase 1 randomized trial of a plant-derived virus‐like particle vaccine for COVID-19	RCT vaccine phase 1	Canada	Ward B.J., et al.	https://www.nature.com/articles/s41591-021-01370-1	NCT04450004	CoVLP (virus-like particle) vaccine candidate produced in plants	To evaluate the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses.
17-May-21	Clin Infect Dis.	The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real‐world data	historical cohort study	Israel	Chodick G., et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab438/6276888	NA	BNT162b2 vaccine	To evaluate the effectiveness of BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality.
14-May-21	Lancet	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	RCT	UK	RECOVERY Collaborative Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00897-7/fulltext	NCT04381936	Convalescent plasma	To evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19
21-May-21	Rev Invest Clin	Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2	RCT	Iran	Hamidi-Alamdari	https://www.clinicalandtranslationalinvestigation.com/files/ric_21_73_3_190-198.pdf	NCT04370288	Methylene Blue	To evaluate the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO2) and respiratory rate (RR).
21-May-21	MedRxiv	REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients	RCT	USA	Weinreich D, et al.	https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v1	NCT04425629	REGEN-COV antibody cocktail (casirivimab with imdevimab)	To evaluate the risk of hospitalization or death, and time to symptom resolution.
22-Apr-21	EClinicalMedicine	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.	RCT	Denmark	Gunst et al.	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00129-2/fulltext	NCT04321096	camostat mesilate	Does camostat mesilate improve clinical outcomes of COVID-19 patients?
16-Apr-21	Critical Care Medicine	Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York A Double-Blind Randomized Trial	RCT	USA	Bennet-Guerrero	https://journals.lww.com/ccmjournal/Abstract/9000/Severe_Acute_Respiratory_Syndrome_Coronavirus_2.95264.aspx	NCT04344535	Convalescent plasma	Does convalescent plasma increases antibodies and improves clinical outcomes of COVID-19 patients?
13-May-21	BMJ	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study	Observational study	UK	Bernal et al.	https://www.bmj.com/content/373/bmj.n1088	NA	Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccine	To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms
20-Apr-2021	JAMA	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19	RCT	USA	Stephenson KE et al	https://pubmed.ncbi.nlm.nih.gov/33704352/	NCT04436276	Ad26.COV2.S vaccine (by Janssen Pharmaceutical Companies)	To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses
11-Mar-2021	J of Medical Virology	Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19	CT	Egypt	Elalfy H et al	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014583/pdf/JMV-9999-0.pdf	NCT04392427	Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc vs supportive treatment	To compare the rate and time of viral clearance in subjects receiving the combination of nitazoxanide, ribavirin, and ivermectin plus zinc versus those receiving supportive treatment.
20-Apr-2021	MedRxiv	Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti- SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study	RCT	France	Gaborit B et al	https://www.medrxiv.org/content/10.1101/2021.04.15.21255549v1.full.pdf	NCT04453384	XAV-19 0.5 mg/kg at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), 2 mg/kg at day 1 (group 3) or placebo	To assess the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2, in COVID-19-related moderate pneumonia
21-Apr-21	NEJM	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	Vaccine RCT III phase	International	Sadoff J et al.	https://www.nejm.org/doi/10.1056/NEJMoa2101544	NCT04505722	Ad26.COV2.S vaccine	To assest the Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
16-Apr-21	Blood	Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia	Vaccine trial	Israel	Herishanu Y, et al.	https://ashpublications.org/blood/article/doi/10.1182/blood.2021011568/475742/Efficacy-of-the-BNT162b2-mRNA-COVID-19-Vaccine-in	NCT04746092	BNT162b2 mRNA COVID19 vaccine	To determine the efficacy of COVID-19 vaccine in patients with CLL.
28-Apr-21	Chinese Medical Journal	Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials	vaccine RCT I/II phase	China	Pan HX, et al.	https://journals.lww.com/cmj/Abstract/9000/Immunogenicity_and_safety_of_a_SARS_CoV_2.98627.aspx	ChiCTR2000038804, ChiCTR2000039462	KCONVAC - SARS-CoV-2 inactivated vaccine	To assess the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults.
22-Apr-21	*JAMA Netw Open.*	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial	RCT	International	Reis G et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044	NCT04403100	hydroxychloroquine or lopinavir-ritonavir	To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting.
5-May-21	MedRxiv	Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial	RCT	Mexico	Fragoso-Saavedra S, et al.	https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ppmedrxiv-21255834	NCT04343963	pyridostigmine	to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19

5-May-21	The Lancet	Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data	Observational study	Israel	Haas et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext	NA	BNT162b2	Real-world effectiveness of two doses of BNT162b2 against SARS-CoV-2
1-May-21	The Lancet	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	Horby et al. (RECOVERY Collaborative Group)	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900676-0	NCT04381936	Tocilizumab	What is the effect of tocilizumab in adult patients admitted to hospital with COVID-19
27-Apr-21	The Lancet Oncology	Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study	Observational study	UK	Manin et al.	https://www.thelancet.com/action/showPdf?pii=S1470-2045%2821%2900213-8	NA	BN162b2 vaccine	To assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer
9-Apr-21	Lancet Respir Med.	Inhaled budesonide in the treatment of early COVID‐19 (STOIC): a phase 2, open-label, randomised controlled trial	RCT 2 phase	UK	Ramakrishnan S., et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext	NCT04416399	inhaled glucocorticoid budesonide	To evaluate the efficacy of the widely used inhaled glucocorticoid budesonide in individuals with early COVID-19 in the community.
30-Mar-21	Lancet	Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	vaccine	UK	Emary K.R.W., et al	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext	NCT04400838	ChAdOx1 nCoV‐19 (AZD1222) vaccine	post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against the variant B.1.1.7.
10-Apr-21	BMC Infectious Diseases	Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial	RCT	Iran	Ranjbar B	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06045-3	IRCT20200204046369N1	Methylprednisolone or dexamethason	To assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients.
8-Apr-2021	MedRxiv	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials	Two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC	China	Pan H et al	https://www.medrxiv.org/content/10.1101/2021.04.07.21253850v1.full.pdf	NCT04758273 AND NCT04756323	KCONVAC	To report the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults.
1-Apr-2021	MedRxiv	INTERIM REPORT: SAFETY AND IMMUNOGENICITY OF AN INACTIVATED VACCINE AGAINST SARS-COV-2 IN HEALTHY CHILEAN ADULTS IN A PHASE 3 CLINICAL TRIAL	Interim analysis of a multicenter phase 3 CT	Chile	Bueno SM et al	https://www.medrxiv.org/content/10.1101/2021.03.31.21254494v1.full.pdf	NCT04651790	CoronaVac	To evaluate safety parameters and immunogenicity against SARS-CoV-2 after immunization with CoronaVac
30-Mar-2021	MedRxiv	A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS	RCT	Argentina	Chahla RE et al	https://www.medrxiv.org/content/10.1101/2021.03.26.21254398v1.full.pdf	NCT04701710	Ivermectin / IotaCarrageenan	To assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2
15-Apr-2021	MedRxiv	Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID- 19 in hospital personnel dedicated to patients care with COVID-19 disease	RCT (CARR-COV-02)	Argentina	CARR-COV2 Trial Group collaborators	https://www.medrxiv.org/content/10.1101/2021.04.13.21255409v1.full.pdf	NCT04521322	Nasal spray containing Iota-Carrageenan (I-C) or placebo for 21 days.	To assess the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients
15-Apr-2021	MedRxiv	Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report	preliminary report	Brazil	De Faria E et al	https://www.medrxiv.org/content/10.1101/2021.04.12.21255308v1.full.pdf	NA	CoronaVac	to report the occurrence of symptomatic COVID-19 in a cohort of healthcare workers (HCW) vaccinated with CoronaVac and to estimate its effectiveness.
8-Apr-2021	EClinicalMedicine	RBD-specific polyclonal F(ab‘)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial	phase 2/3, double-blind, placebo-controlled, multicenter clinical	Argentina	Lopardo et al	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037439/pdf/main.pdf	NCT04494984	Equine poly- clonal antibodies (EpAbs)	To analyze the safety and efficacy of specific anti SARS-COV-2 EpAbs in hospitalized patients with moderate and severe COVID-19 disease
12-Apr-2021	Int J of Infectious Diseases	Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial	double-blind, single-center study	Iran	Siami Z et al	https://pubmed.ncbi.nlm.nih.gov/33878462/	NA	Diphenhydramine Compound (Diphenhydramine + Ammonium Chloride) plus standard of care or Diphenhydramine alone and standard of care groups	Quaternary ammonium compounds have been demonstrated to have antiviral effects and may be of use against SARS-CoV-2 infections.
13-Apr-2021	Scientific reports	Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial	three-armed, individually-randomized, open-label, controlled trial	Iran	Darazam IA et al	https://www.nature.com/articles/s41598-021-86859-y	NCT04343768	IFNβ1a and IFNβ1b	To determine any possible effects and safety concerns of the two most promising exogenously administrable IFNs on the course and outcomes of patients hospitalized with severe COVID-19.
30-Mar-2021	Nature Comm	Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial	randomized, single-blind, placebo-controlled trial	USA	Jagannathan P et al	https://pubmed.ncbi.nlm.nih.gov/33785743/	NCT04331899	180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda)	To evaluate the efficacy of Lambda in reducing the duration of viral shedding in outpatients.

24-Mar-21	The Lancet Infectious Diseases	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials	RCT - vaccine - phase I/II	China	ShilongYang, et al.	https://www.sciencedirect.com/science/article/S1473309921001274/pii/?via%3Dihub	NCT04445194 and NCT04466085	ZF2001 Vaccine - protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen	To assess the safety and immunogenicity of this vaccine, ZF2001, and determine the appropriate dose and schedule for an efficacy study.
25-Mar-21	Therapeutic Advances in Respiratory Disease	Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis	meta-analysis	Mexico	Zuñiga RAA, et al.	https://journals.sagepub.com/doi/10.1177/17534666211007214	NA	remdesivir, chloroquine, hydroxychloroquine, lopinavir, ritonavir, dexamethasone, and convalescent plasma,	To assess the clinical effectiveness of drugs used in hospitalized patients with COVID-19 infection.
25-Mar-21	JAMA	Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure The HENIVOT Randomized Clinical Trial	RCT	International	Domenico Luca Grieco	https://jamanetwork.com/journals/jama/fullarticle/2778088	NCT04502576	oxygen	To assess whether helmet noninvasive ventilation can increase the days free of respiratory support in patients with COVID-19 compared with high-flow nasal oxygen alone.
18-Mar-21	JAMA	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial	RCT	Iran	INSPIRATION Investigators	https://jamanetwork.com/journals/jama/fullarticle/2777829	NCT04486508	enoxaparin, 1 mg/kg daily vs standard prophylactic anticoagulation enoxaparin, 40 mg daily	To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU)
8-Mar-2021	Lancet Infect Dis	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial	Vaccine trial Phase II	India	Ella R., et al.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext	NCT04471519	BBV152 (Bharat Biotech) vaccine	To evaluate the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152.
4-Mar-2021	JAMA	Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19A Randomized Clinical Trial	RCT Phase III	Colombia/USA	Lopez-Medina E., et al.	https://jamanetwork.com/journals/jama/fullarticle/2777389	NCT04405843	Ivermectin	To determine whether ivermectin is an efficacious treatment for mild COVID-19.
4-Mar-2021	Lancet Respir Med	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	RCT Phase III	International	Lescure FX., et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext	NCT04327388	Sarilumab	To assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.
4-Mar-2021	Lancet	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	RCT Phase III	UK	PRINCIPLE Trial Collaborative Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00461-X/fulltext	ISRCTN86534580	Azithromycin	To assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications.
1-Mar-2021	Antimicrob Agents Chemother	Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2	RCT Phase I	USA	Painter W. P., et al.	https://aac.asm.org/content/early/2021/02/24/AAC.02428-20	NCT04392219	Molnupiravir, EIDD-2801/MK-4482, prodrug of the active antiviral ribonucleoside analog 14ß-d-N4-hydroxycytidine (NHC; EIDD-1931)	Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebocontrolled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.
11-Mar-2021	JAMA	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19	Vaccine trial Phase I	USA	Kathryn E. Stephenson	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 | Vaccination | JAMA | JAMA Network	NCT04436276	Ad26.COV2.S Vaccine (Janssen)	To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses.
10-Feb-2021	Signal Transduct Target Ther	Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial	Vaccine trial Phase I/II	China	Shi et el.	https://pubmed.ncbi.nlm.nih.gov/33568628/	NCT04288102	Human umbilical cord-derived mesenchymal stem cells	To assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.
9-Feb-2021	Vaccine	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine	RCT phase II	US	LaurenceChu	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine - ScienceDirect	NCT04405076	mRNA-1273 vaccine	To evaluate the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2.
03-Mar-21	Plos Med	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial	RCT	Chile	Balcells MA et al	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929568/pdf/pmed.1003415.pdf	NCT04375098	Convalescent Plasma	To evaluate the efficacy and safety of early Convalescent Plasma therapy in COVID-19 progression
07-Mar-21	Thrombosis and Haemostasis	Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial	RCT	Mexico	Gonzalez Ochoa AJ et al	https://pubmed.ncbi.nlm.nih.gov/33677827/	ISRCTN59048638	Oral dose of sulodexide (500 LRU twice a day) or placebo for 21 days	To evaluate the effect of sulodexide when used in the early clinical stages of COVID-19
16-Mar-21	NEJM	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	RCT	South Africa	Madhi SA et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2102214?articleTools=true	NCT04444674	ChAdOx1 nCoV-19 vaccine (AZD1222)	To assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa.

24-Feb-21	NEJM	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	Vaccine	Israel	Dagan N., et al.	https://www.nejm.org/doi/10.1056/NEJMoa2101765	NA	BNT162b2 mRNA Covid-19 Vaccine	Evaluation of the effectiveness of the BNT162b2 mRNA vaccine based on data from Israel's largest health care organization.
19-Feb-21	Lancet	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine: a pooled analysis of four randomised trials	Vaccine	UK	Voysey M., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext	NA	ChAdOx1 nCoV-19 vaccine	Exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. - Immunogenicity and protection afforded by the first dose, before a booster dose has been offered.
18-Feb-21	Lancet	Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	Vaccine	Israel	Amit S., et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext	NA	BNT162b2 vaccine	To examine early reductions in SARS-CoV-2 infection and COVID19 rates in vaccinated HCWs.
28-Feb-21	JAMA	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis	Metaanalysis	International	Janiaud et al.	https://jamanetwork.com/journals/jama/fullarticle/2777060	NA	convalescent plasma	Is treatment with convalescent plasma associated with improved clinical outcomes?
17-Feb-21	JAMA	Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19. A Randomized Clinical Trial	RCT	Brazil	Murai et al.	Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA | JAMA Network	NCT04449718	Vitamin D3	To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19.
12-Feb-21	JAMA	Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection The COVID A to Z Randomized Clinical Trial	RCT	US	Thomas et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776305	NCT04342728	Zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.	To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.
4-Feb-21	JAMA	Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19. A Randomized Clinical Trial	RCT	France	Guenezan	https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2775984	NCT04371965	Povidone iodine (PI) solutions.	Whether nasopharyngeal application of PI could reduce the viral load of patients with nonsevere coronavirus disease 2019 (COVID-19) symptoms.
22-Jan-21	Respiration	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial	RCT	China	Tang et al.	https://pubmed.ncbi.nlm.nih.gov/33486496/	NCT04273321	methylprednisolone	Efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19
Jan-21	European Respiratory Journal	Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial	RCT	Brazil	Rocco et al.	https://erj.ersjournals.com/content/erj/early/2021/01/04/13993003.03725-2020.full.pdf	NCT04552483	nitazoxanide	Efficacy and safety of nitrazoxanide in COVID-19 patients
Jan-21	Stem Cell Transplantation Medicine	Umbilical cord mesenchymal stem cells for COVID-19 acuterespiratory distress syndrome: A double-blind, phase 1/2a,randomized controlled trial	RCT	USA	Lanzoni et al.	https://stemcellsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/sctm.20-0472	NCT04355728	mesenchymal stem cell	Safety of MSC in COVID-19 patients
1-Mar-21	MedRxiv	Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults	RCT	USA	Neil Formica et al	https://www.medrxiv.org/content/10.1101/2021.02.26.21252482v1.full.pdf	NCT04368988	NVX-CoV2373 vaccine	Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373
25-Jan-21	Archives of Virology	Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study	RCT	Egypt	Dabbous HM et al	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829645/pdf/705_2021_Article_4956.pdf	NCT04351295	chloroquine and favipiravir	To evaluate the efficacy of favipiravir
25-Feb-21	NEJM	Dexamethasone in Hospitalized Patients with Covid-19	RCT	UK	Horby P et al (RECOVERY Group)	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?articleTools=true	NCT04381936; ISRCTN number, 50189673	dexamethasone	To evaluate the effects of potential treatments in patients hospitalized with Covid-19 at
25-Feb-21	NEJM	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	RCT	USA	Rosas IO et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028700?articleTools=true	NCT04320615	tocilizumab	To assess the efficacy and safety of tocilizumab in hospitalized patients with severe Covid-19 pneumonia
25-Feb-21	NEJM	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19	RCT	UK	Gordon AC et al	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433?articleTools=true	REMAP-CAP ClinicalTrials.gov number, NCT02735707	tocilizumab and sarilumab	To assess the efficacy of interleukin-6 receptor antagonists in critically ill patients with Covid-19
20-janv-21	BMJ	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled tria	RCT	Brazil	Veiga, V.C. et al.	https://www.bmj.com/content/372/bmj.n84	NCT04403685	tocilizumab	Does tocilizumab improves clinical outcomes for patients with severe or COVID-19?.
13-janv-21	NEJM	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	vaccine Phase I/IIa	USA	Sadoff J., et al.	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM	NCT04436276. opens in new tab.	Ad26.COV2.S vaccine	The safety and immunogenicity profiles of Ad26.COV2

13-janv-21	NEJM	Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients	expanded access program	USA	Joyner et al.	https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf	NCT04338360	Convalescent plasma	To assess whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death. Primary outcome: death within 30 days after plasma transfusion.
11-nov-20	Postgraduate Medical Journal	Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)	RCT	India	Rastogi et al.	https://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065	NCT04459247	Vitamin D	Do high doses of cholecalciferol lead to SARS-CoV-2 negativity in greater proportions?
29-janv-21	The Lancet	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	Phase I vaccine trial	Multinational	Richmond et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext	NCT04405908	S-Trimer (SCB-2019)	Dose-finding and adjuvant justification of SCB-2019 vaccine
02-févr-21	The Lancet	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia	Phase III vaccine trial	Russia	Logunov et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext	NCT04530396	Gam-COVID-Vac (Sputnik V)	Efficacy and safety of Gam-COVID-Vac
06-janv-21	NEJM	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults	RCT	Argentina	Libster R, et al.	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults | NEJM	NCT04479163	Convalescent plasma	Does convalescent plasma reduce the development of severe respiratory disease?
30-déc-21	NEJM	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine	Vaccine - phase III	USA	Baden LR, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035389?query=featured_coronavirus	NCT04470427	mRNA-1273 SARS-CoV-2 Vaccine	Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
12-janv-21	MedRxiv	Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial	RCT	Multinational	Holubovska et al.	https://www.medrxiv.org/content/10.1101/2021.01.05.21249237v1.full-text	NCT04682873	enisamium	Efficacy and safety of enisamium at COVID-19 patients
20-janv-21	MedRxiv	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study	Vaccine trial phase I/II	Multinational	Goepfert et al.	https://www.medrxiv.org/content/10.1101/2021.01.19.20248611v1	NCT04537208	CoV2 preS dTM vaccine	Safety and imunogenicity of CoV2 preS dTM vaccine
09-janv-21	Annals of Intensive Care	Pilot trial of high-dose vitamin C in critically ill COVID-19 patients	RCT	China	Zhang et al.	https://link.springer.com/article/10.1186/s13613-020-00792-3	NCT04264533	Vitamin C	Effect of high doses of vitamin C
01-févr-21	International Journal of Infectious Diseases	Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial	RCT	India	Udwadia et al.	https://www.sciencedirect.com/science/article/pii/S120197122032453X?via%3Dihub	CTRI/2020/05/025114	favipiravir	Efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19
08-déc-20	Lancet	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	phase I/II/III vaccine trial	Multinational	Voysey et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext	ISRCTN89951424, NCT04324606, NCT04400838, and NCT04444674	ChAdOx1 nCoV-19 vaccine	To test the safety and efficacy of the ChAdOx1 nCoV-19 vaccine
11-déc-20	NEJM	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	RCT	USA	Kalil A.C., et al	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | NEJM	NCT04401579	Baricitinib plus Remdesivir	Effect of baricitinib (≤14 days) plus remdesivir (≤10 days) vs. remdesivir alone in hospitalized adults with Covid-19
17-déc-20	NEJM	Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia	RCT	USA	Salama et al.	https://www.nejm.org/doi/10.1056/NEJMoa2030340	NCT04372186	tocilizumab	To test the safety and efficacy of tocilizumab in hospitalized patients with Covid-19 pneumonia
31-déc-20	Preprint	Exogenous Surfactant Versus Placebo in the Treatment of Moderate and Severe ARDS in COVID19: The Pilot Study of a Clinical Trial	RCT	Iran	Ghahremani et al.	https://assets.researchsquare.com/files/rs-136365/v1/adcad24b-f7ed-477b-a235-235f84f8ce1b.pdf	IRCT20091201002804N12	surfactant	Is surfactant effective in COVID-19 paients?
02-déc-20	NEJM	Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results	RCT	Multinational	WHO Soidarity Trial Consortium	Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | NEJM	NCT04315948	remdesivir, hydroxychloroquine (HCQ), lopinavir, and interferon beta-1a (IFN)	WHO mortality trial of four repurposed antiviral drugs — remdesivir, hydroxychloroquine (HCQ), lopinavir, and interferon beta-1a (IFN)— in patients hospitalized with Covid-19.
03-déc-20	NEJM	Durability of Responses after SARS-CoV-2 mRNA1273 Vaccination	Phase I vaccine trial	USA	Widge A.T., et al.	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination | NEJM	NCT04283461	mRNA 1273 vaccine	mRNA 1273 vaccine immunogenicity 3 months after second vaccination
24-déc-20	EClinicalMedicine	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial	Phase I vaccine trial	USA/UK	Tebas et al.	https://www.sciencedirect.com/science/article/pii/S2589537020304338	NCT04336410	INO-4800 DNA vaccine	Safety and immunogenicity of INO-4800 vaccine
17-déc-20	Nature Med.	Phase 1/2 trial of SARSCoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	Phase I/II vaccine trial	UK	Barrett J.R., et al.	https://www.nature.com/articles/s41591-020-01179-4	NCT04400838	ChAdOx1 nCoV-19 vaccine AZD1222	Safety and exploratory humoral and cellular immunogenicity of the AZD1222 vaccine

17-déc-20	NEJM	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19	RCT	USA	Weinreich D.M	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM	NCT04425629	REGN-COV2 antibody cocktail	Interim study results: effects of high viral loads with complications and death from coronavirus disease 2019 (Covid-19)-REGN-COV2 effects on outpatients
22-déc-20	preprint - BMJ	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report	Phase I/II vaccine trial	India	Raches et al.	https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1	NCT04471519	inactivated SARS-CoV-2 vaccine, BBV152	To test the immunogenicity and safety of BBV152: 3 µg and 6 µg with Algel-IMDG.
22-déc-20	NEJM	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19	RCT	Denmark	ACTIV-3/TICO LY-CoV555 Study Group	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | NEJM	NCT04501978	LY-CoV555	To test the effect of this antibody in patients who are hospitalized with Covid-19.
10-déc-20	NEJM	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	RCT	USA	Stone J.H., et al	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 | NEJM	NCT04356937	tocilizumab	To test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
14-déc-20	BMC Infect Dis	Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.	RCT	Iran	Marzieh et al.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w	IRCT20180725040596N2	Arbidol (Umifenovir)	To determine the effect of Arbidol (ARB) on COVID-19 disease.
23-déc-20	Trials	Interferon ß-1a (IFNß-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.	RCT	Italy	Bosi et al.	https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04864-4	EudraCT 2020-002458-25, NCT04449380	Interferon ß-1a (IFNß-1a)	To test the efficacy of Interferon-β-1a (IFNβ-1a), in COVID-19 patients in an open label, randomized clinical trial.
10-déc-20	NEJM	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	phase II vaccine trial	USA	Polack F.P., et al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM	NCT04368728. opens in new tab	BNT162b2 vaccine	To evaluate the efficacy and safety of BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membraneanchored SARS-CoV-2 fulllength spike protein.
18-déc-20	Journal of Antimicrobial Chemotherapy	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	RCT	Iran	Roozbeh et al.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa501/6041772?login=true	IRCT20200403046926N1	sofosbuvir, daclatasvir	Is sofosbuvir/daclatasvir effective in COVID-19 patiets?
16 November 2020	Critical Care Explorations	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019	RCT	USA	George Sakoulas, et al.	https://journals.lww.com/ccejournal/Fulltext/2020/11000/Intravenous_Immunoglobulin_Plus_Methylprednisolone.14.aspx	NCT04411667	Immunoglobulins	To asses the efficacy and safety of IV immunoglobulin in hospitalized COVID-19 patients.
23 November 2020	Biological Trace Element Research	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial	RCT	Egypt	Sherief Abd-Elsalam, et al.	https://link.springer.com/article/10.1007/s12011-020-02512-1	NCT04447534	Zinc, Hydroxychloroquine	To evaluate the effect of combining chloroquine/hydroxychloroquine and zinc in the treatment of COVID-19 patients.
17-nov	MedRxiv	Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized 3 Controlled Trial	RCT	Brazil	Murai et al.	https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1.full.pdf	NCT04449718	Vitamin D3	To determine if vitamin D3 supplementation can reduce hospital length of stay in hospitalized patients with severe COVID-19?
23-nov	MedRxiv	Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial	RCT	USA	Jagannathan et al.	https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1.full.pdf	NCT04331899	Peginterferon Lambda-1a	To determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding or symptoms in patients with mild to moderate COVID-19.
21-nov	MedRxiv	Prevention of severe COVID-19 in the elderly by early hightiter plasma	RCT	Argentina	Libster et al.	https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1.full.pdf	NCT04479163	Convalescent plasma	To evaluate the efficacy of convalescent plasma with high titers of SARS-CoV2 antibody administered within 72 hours of mild symptoms to elderly patients with Covid-19
02-déc	MedRxiv	A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19	RCT	India	Kumar et al.	https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.full.pdf	CTRI/2020/05/024959	Itolizumab	To estimate the efficacy and safety of Itolizumab in the treatment of cytokine release syndrome in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.
18-nov	MedRxiv	5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARSCoV-2 Positive Men	RCT	Brazil, USA	Cadegiani et al.	https://www.medrxiv.org/content/10.1101/2020.11.16.20232512v1.full.pdf	NCT04446429	Dutasteride	To determine if 5-alpha-reductase inhibitors (5ARis) are a beneficial treatment for COVID-19 if given after SARS-CoV-2 infection

11-nov	International Immunopharmacology	Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study	RCT	Mexico	Maldonado et al.	https://reader.elsevier.com/reader/sd/pii/S1567576920336766?token=EDD4B561C8D7F700793B55AFFA9EE8F0CD28010BE3E0CADC0EF90237E4EF73330CF63D0FDA8F33F2F0AD9CA7536BD33F	COF-002495	Pentoxifylline	To test the effect Pentoxifylline (PTX) on parameters such as LDH, lymphocyte count, days of hospitalization, mortality, and the need for intubation on patients with severe and moderate COVID-19
02-déc-20	NEJM	Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results	RCT	Multinational	WHO Solidarity Trial Consortium	https://www.nejm.org/doi/10.1056/NEJMoa2023184	ISRCTN83971151, NCT04315948	hydroxychloroquine, lopinavir/ritonavir, interferon beta1, remdesivir	effects of drugs on in-hospital mortality
24-nov-20	NEJM	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19	RCT	Spain	Mitjà et al.	https://www.nejm.org/doi/10.1056/NEJMoa2021801	NCT04304053	Hydroxychloroquine	Does postexposure prophylaxis with hydroxychloroquine prevent SARS-CoV-2 infection?
24-nov-20	NEJM	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia	RCT	Argentina	Simonovich et al.	https://www.nejm.org/doi/10.1056/NEJMoa2031304	NCT04383535	Convalescent plasma	Is treatment with convalescent plasma associated with improved clinical outcomes in COVID-19 patients?
19-nov-20	The Lancet	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	phase II/III vaccine trial	UK	Ramasamy et al.	https://www.sciencedirect.com/science/article/pii/S0140673620324661?via%3Dihub	NCT04400838, ISRCTN 15281137	ChAdOx1 vaccine	Safety and immunogenicity of ChAdOx1 vaccine in young and old adults
18-nov-20	Lancet Infect. Dis.	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.	I/II vaccine trial	China	Zhang et al.	https://www.sciencedirect.com/science/article/pii/S1473309920308434?via%3Dihub	NCT04352608	CoronaVac vaccine	Safety, tolerability and immunogenicity of CoronaVac vaccine
04-nov	MedRxiv	Randomized controlled trial of convalescent plasma therapy against standard therapy in 2 patients with severe COVID-19 disease	RCT	Bahrain, Ireland	Al Qahtani et al.	https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full.pdf	NCT04356534	Convalescent plasma	Pilot study designed to inform the design of a definitive phase 3 clinical trial.
12/11/2020	MedRxiv	Peginterferon-lambda for the treatment of COVID-19 in outpatients	RCT	Canada	Feld et al.	https://www.medrxiv.org/content/10.1101/2020.11.09.20228098v1.full.pdf	NCT04354259	Peginterferon	To evaluate a single subcutaneous injection of peginterferon-lambda in outpatients with COVID-19.
13-nov	International Immunopharmacology	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial	RCT	Iran	Tabarsi et al.	https://reader.elsevier.com/reader/sd/pii/S1567576920336729?token=13C23CAB7F2F51222936F6967643ECEC50F680C6C1B600298B1211225F0DFEC4733E630469CDAF7A7C229585B41FD1EE	IRCT20151227025726N20	Intravenous Immunoglobulin	To investigate the potential usefulness of IVIg for the management of severe cases of Covid-19.
9 November 2020 (preprint)	International Journal of Infectious Diseases	Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia	RCT	Oman	Faryal Khamis, et al.	https://www.sciencedirect.com/science/article/pii/S1201971220323195?via%3Dihub	NA	Favipiravir, interferon beta-1b	To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia.
Preprint	Clinical Infectious Diseases	Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults	Phase 2 vaccine trial	China	Yanchun Che, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1703/5962856	NCT04412538	Inactivated vaccine	Assess the safety and immunogenitcity of this inactiviated vaccine
6 November 2020 (in press)	International Journal of Antimicrobial Agents	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study	RCT	India	Deba Prasad Dhibar, et al.	https://www.sciencedirect.com/science/article/pii/S0924857920304350?via%3Dihub	NCT04408456	Hydroxychloroquine	To evaluate the efficacy of PEP with HCQ for the prevention of COVID-19 in asymptomatic non-HCW individuals who were at risk for SARS-CoV-2 infection
Preprint	MedRxiv	Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants	Phase 1 vaccine Trial	Canada	Brian J Ward, et al.	https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1	NCT04450004	CoVLP vaccine	To assess the safety, tolerability, and immunogenicity of CoVLP at three dose levels unadjuvanted or adjuvanted with either CpG 1018 or AS03 in healthy adults 18 to 55 years of age.
27 October 2020	E-Clinical Medicine (Lancet)	An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19	RCT	China	Weihui Fu, et al.	https://www.sciencedirect.com/science/article/pii/S2589537020302911?via%3Dihub	ChiCTR2000030262	IFN-κ plus TFF2	To evaluate the efficacy and safety in patients with moderate COVID-19 f the combination of IFN-κ plus TFF2
12-nov-20	The Lancet Respiratory Medicine	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial	RCT	UK	Monk et al.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext	2020-001023-14, NCT04385095	INF-beta 1a	Efficacy and safety of inhaled nebulised interferon beta-1a
12-nov-20	JAMA	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19A Randomized Clinical Trial	RCT	USA	Lenze et al.	https://jamanetwork.com/journals/jama/article-abstract/2773108	NCT04342663	Fluvoxamine	Determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease

Preprint	The Lancet	Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial	RCT	Argentina	Krolewiecki et al.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649	NCT004381884	Ivermectin	Does ivermectin reduce the viral load?
27-oct	MedRxiv	Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.	RCT	India	Bajpai et al.	https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1.full.pdf	NCT04346446	Convalescent plasma	To compare the efficacy and safety of convalescent plasma with fresh frozen plasma (FFP) in severe COVID-19 patients
21-oct	MedRxiv	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19	RCT	France	Dubée et al. for the HYCOVID study group	https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1.full.pdf	NCT04325893	Hydroxychloroquine	To evaluate the efficacy and safety of hydroxychloroquine in adult patients with mild-to-moderate COVID-19 at risk of worsening.
23-oct	MedRxiv	Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo controlled trial	RCT	Brazil	Rocco et al.	https://www.medrxiv.org/content/10.1101/2020.10.21.20217208v1.full.pdf	NCT04552483	Nitazoxanide	To evaluate whether early nitazoxanide therapy would be effective in accelerating symptom resolution in patients with mild COVID-19.
27-oct	MedRxiv	Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq	RCT	Iraq	Hashim et al.	https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.full.pdf	NCT04591600	Ivermectin + Doxycycline	To test the combinational therapy of Ivermectin and Doxycycline in treating COVID-19 patients at different stages of the disease.
21-oct	MedRxiv	Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial	RCT	China	Shi et el.	https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2.full.pdf	NCT04288102	human umbilical cord-derived mesenchymal stem cells	To assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage.
26-oct	Lancet pre-print	Umbilical Cord Mesenchymal Stem Cells for COVID-19 ARDS: A Double Blind, Phase 1/2a, Randomized Controlled Trial	RCT	USA	Lanzoni et al.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875	NCT04355728	human umbilical cord-derived mesenchymal stem cells	To determine safety and explore efficacy of Umbilical Cord (UC)-MSC infusions in COVID-19 ARDS.
01-nov	J Antimicrob Chemother	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis	Meta-analysis	UK/Iran	Simmons et al.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa418/5924537	N/A	sofosbuvir/daclatasvir	To determine whether sofosbuvir/daclatasvir-based regimens improve clinical outcomes of patients with moderate or severe COVID-19.
26-oct	Lancet pre-print	Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19	RCT	Russia	Ruzhentsova et al.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907	NCT04501783	Favipiravir	To evaluate the efficacy and safety of favipiravir for treatment of mild to moderate COVID-19
01-nov-20	Imunopathology and infectious diseases	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality	RCT	USA	Salazar et al.	https://www.sciencedirect.com/science/article/pii/S0002944020303709?via%3Dihub		Convalescent plasma	Efficacy of COVID-19 convalescent plasma transfusion for severe and/or critical COVID-19.
21-oct-20	NEJM	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	RCT	USA	Stone et al.	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028836	NCT04356937	Tocilizumab	Does tocilizumab prevent intubation or death?
20-oct-20	JAMA Internal Medicine	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial	RCT	France	Hermine et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187	NCT04331808	Tocilizumab	To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia
20-oct-20	JAMA Internal Medicine	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 PneumoniaA Randomized Clinical Trial	RCT	Italy	Salvarani et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186	NCT04346355; EudraCT Identifier: 2020-001386-37.	Tocilizumab	To evaluate the effect of early tocilizumab administration
01-oct-20	International Journal of Research in Pharmaceutical Sciences	Efficacy of umifenovir in the treatment of mild and moderate covid-19 patients	Randomized clinical study	Kyrgizstan	Yethindra et al.	https://pharmascope.org/ijrps/article/view/2839/6116	NA	Umifenovir	To evaluate the efficacy of umifenovir in mild and moderate COVID-19 patients
8 October 2020	NEJM	Remdesivir for the Treatment of Covid-19 — Final Repor	RCT	USA	John H. Beigel, et al.	https://www.nejm.org/doi/10.1056/NEJMoa2007764	NCT04280705	Remdesivir	To evaluate the efficacy of remdesivir in shortening time to recovery in hospitalized COVID-19 patients.
15 October 2020	Lancet	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	Phase 1/2 vaccine trial	China	Shengli Xia, et al.	https://www.sciencedirect.com/science/article/pii/S1473309920308318?via%3Dihub	ChiCTR2000032459.	BBIBP-CorV	To assess the safety and immunogenicity of an inactivated SARS CoV2 vaccine
15 October 2020	MedRiXV	Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results	RCT	International	Hongchao Pan, et al.	https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1	ISRCTN83971151	Lopinavir/ritonavir, remdesivir, hydroxychloroquine, interferon	Are repurposed andiviral drugs effective in treating COV ID19?
28 October 2020	NEJM	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	Phase 2 RCT	USA	Peter Chen, et al.	https://www.nejm.org/doi/10.1056/NEJMoa2029849	NCT04427501	Monoclonal antibody, LY-CoV555	To assess the safety and dose response through reduction of viral load of monoclonal antibody LY-CoV555 in patients with mild or moderate COVID-19
21 October 2020	Lancet preprint	Self-Proning in COVID-19 Patients on Low-Flow Oxygen Therapy: A Cluster Randomised Controlled Trial	RCT	Switzerland	Aileen Kharat, et al.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3692538	SNCTP000003718	Self-proning	To assess if a simple incentive to self prone for a maximum of 12 h per day would decrease oxygen needs in patients admitted for COVID-19 pneumonia on low-flow oxygen therapy.
11 September 2020	International Forum of Allergy and Rhinology	Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019	RCT	USA	Kyle S. Kimura, et al.	https://onlinelibrary.wiley.com/doi/10.1002/alr.22703	NA	Nasal irrigations	To assess if nasal irrigation can reduce symptoms and viral shedding in mild and moderate COVID-19 patients

Preprint	MedRiXV	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia	RCT	USA	Carlos Salama, et al.	https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1	NCT04372186	Tocilizumab	To assess the safety and efficacy of tocilizumab in patients hospitalized and non-ventilated with Covid-19 pneumonia.
21 October 2020	BMC Infectious Diseases	The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial	RCT	Iran	Naser Gharebaghi, et al.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05507-4	IRCT20200501047259N1	Immunoglobulin gamma	To evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.
28 September 2020	Lancet	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	RCT	Netherlands	Alexander P J Vlaar, et al.	https://www.thelancet.com/action/showPdf?pii=S2665-9913%2820%2930341-6	NCT04333420	Vilobelimab	Phase 2 study to explore the potential benefit and safety of IFX-1 (vilobelimab) in patients with severe COVID-19.
29 September 2020	NEJM	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	Vaccine trial Phase 1	USA	Evan J. Anderson, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2028436	NCT04283461	mRNA-1273 vaccine	Is the SARS CoV-2 mRNA 1273 safe and well tolerated in older adults and does it ellicit an immune response?
30 September 2020 -pre-approved	Nature	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses	Vaccine trial Phase 1 and 2	Germany	Ugur Sahin, et al.	https://www.nature.com/articles/s41586-020-2814-7	NCT04380701	BNT162b1 vaccine	Does the BNT162b1 vaccine elicit both antibody and T-cell response in healthy adults?
Preprint	Research Square	Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients	RCT	China	Chuan Li, et al.	https://assets.researchsquare.com/files/rs-65224/v1/22886bf0-ce06-4d42-aeb6-c73ebb7c2003.pdf	ChiCTR2000029638	Engineered interferon alpha	To evaluate the efficacy and safety of recombinant super-compound interferon versus traditional interferon alpha in patients with moderate to severe COVID-19
24 August 2020	International Immunopharmacology	Interferonβ-1b in treatment of severe COVID-19: A randomized clinical trial	RCT	Iran	Hamid Rahmani, et al.	https://www.sciencedirect.com/science/article/pii/S1567576920323304?via%3Dihub	IRCT20100228003449N27	Interferon β-1b	To evaluate the efficacy and safety of interferon (IFN) β-1b in the treatment of patients with severe COVID-19
30 September 2020	JAMA	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers	RCT	USA	Benjamin S Abella, et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265	NCT04329923	Hydroxychloroquine	To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy
4 September 2020	BMJ	Drug treatments for covid-19: living systematic review and network meta-analysis	Systematic review	International collaboration	Reed AC Siemieniuk, et al.	https://www.bmj.com/content/370/bmj.m2980	NA	All treatments	To compare the effects of treatments for coronavirus disease 2019 (covid-19).
15-oct	Virus Research	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials	Meta-analysis	USA, Japan	Yokoyama et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437510/pdf/main.pdf	N/A	Remdesivir	To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care.
06-sept	MedRxiv	An in-depth investigation of the safety and immunogenicity of an inactivated 2 SARS-CoV-2 vaccine	Phase 1 RCT	China	Pu et el.	https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf	NCT04412538	Vaccine	To investigate the safety and immunogenicity of an inactivated viral vaccine in immunized individuals in a phase I trial, especially focusing on safety with regard to the immunopathology of the vaccine.
11-oct	MedRxiv	Clearing the fog: Is Hydroxychloroquine effective in reducing Corona virus disease-2019 progression: A randomized controlled trial	RCT	Pakistan	Mehmood Kamran et al.	https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v2.full.pdf	NCT04491994	Hydroxychloroquine	To assess the efficacy of HCQ in reducing disease progression in mild COVID-19
05-oct-20	The Lancet	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	Horby et al. (RECOVERY GROUP)	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932013-4	ISRCTN 50189673, NCT04381936	lopinavir/ritonavir	Whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19
20-sept-20	EClinicalMedicine	An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19	RCT	China	Fu et al.	https://www.sciencedirect.com/science/article/pii/S2589537020302911?via%3Dihub	ChiCTR2000030262	IFN-κ , TFF2	Efficacy and safety of IFN-κ and TFF2 in COVID patients.
25-sept	MedRxiv	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial	Phase 1/2a RCT	Netherlands, Belgium, USA	Sadoff et al.	https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf	NCT04436276	Vaccine: non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike protein of SARS-CoV-2	To evaluate the efficacy of a single vaccination of $5x10^{10}$ vp of Ad26.COV2.S
21-sept	MedRxiv	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial	RCT	USA	Rajasingham et al.	https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1.full.pdf	NCT04328467	Hydroxychloroquine	To determine the effectiveness of hydroxychloroquine as pre-exposure prophylaxis in healthcare workers at high-risk of SARS-CoV-2 exposure
22-sept	MedRxiv	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical 3 Response in Covid-19 Patients with Pneumonia. A Randomized and 4 Controlled Clinical Trial	RCT	Cuba	Cruz et al.	https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v2.full.pdf	IG/CIGB300I/CV/2001, ATENEA-Co-300 trial	Anti-CK2 Synthetic Peptide, CIGB-325	To explore safety and efficacy of CIGB-325, an anti-CK2 peptide, in COVID-19 patients.
15-oct	Virus Research	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials	Meta-analysis	USA, Japan	Yujiro Yokoyama et al.	https://www.sciencedirect.com/science/article/pii/S0168170220310443?via%3Dihub	N/A	Remdesivir	To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care.

24 July 2020	Clinical Infectious Diseases	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care	RCT vs cohort	USA	Susan A. Olender, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1041/5876045	NCT04292899 and EUPAS34303	Remdesivir	Efficacy of remdesivir in COVID19 patients
17 November 2020	Antimicrobial Agents Chemotherapy	A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19	RCT	Japan	Yohei Doi, et al.	https://aac.asm.org/content/early/2020/09/16/AAC.01897-20	jRCTs041190120	Favipiravir	Assess the efficacy of favipiravir in asymptomatic or mild COVID19 patients in viral clearance, and resolution of symptoms
24-sept	Virology Journal	Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis	Systematic review & meta-analysis	Nepal	Dhan Bahadur Shrestha et al.	https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z	N/A	Favipiravir	To evaluate the efcacy and safety of the drug Favipiravir as a treatment for COVID-19.
20 September 2020	Thrombosis Research	Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	RCT	Brazil	Anna Cristina Bertoldi Lemos, et al.	https://www.thrombosisresearch.com/article/S0049-3848(20)30530-2/fulltext#%20	REBEC RBR-949z6v	Enoxaparin, anticoagulants	To compare therapeutic enoxaparin treatment to standard prophylactic anticoagulant treatment in severe COVID19
Preprint	Clinical Infectious Diseases	Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial	RCT	China	Wang, et al	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1417/5909448	ChiCTR 2000030058	Leflunomide	To evaluate the efficacy and safety of leflunomide to treat COVID-19 patients with prolonged post-symptomatic viral shedding.
26 August 2020	Clinical Microbiology and Infection	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis	Systematic Review and Meta-analysis	France, Switzerland	Thibault Fiolet, et al.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltext	NA	Chloroquine, hydroxychloroquine, azithromycin	To assess the effect of chloroquine and hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients
Preprint	MedRxIV	Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore	RCT	Singapore	Chaminda Jayampath Seneviratne, et al.	https://www.medrxiv.org/content/10.1101/2020.09.14.20186494v1	NA	Mouth wash	To evaluate and compare different commercial moutwash solutions and their effect on reducing salivary viral load
Preprint	MedRxIV	Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial	RCT	Chile	María Elvira Balcells, et al.	https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1	NCT04375098	Covalescent Plasma	Evaluate the safety and efficacy of convalescent plasma and compare an early vs deferred treatement strategy
19 July 2020	Bioimpacts	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial	RCT	Iran	Khalil Ansarin	https://bi.tbzmed.ac.ir/Article/bi-23240	IRCT20200311704679 7N4	Bromhexine	Evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19.
12-sept-20	Expert Review of Anti-Infective Therapy	The effect of antivirals on COVID-19: a systematic review	Systematic review	Hussain et al.	UK	https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1823832?journalCode=ierz20	NA	Antivirals	Identify studies pertaining to antivirals in COVID-19 patients and review the clinical outcomes
23 September 2020	Clinical Infectious Diseases	Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19	RCT	Brazil	Julio Cesar Garcia de Alencar, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1443/5910353			To determine whether NAC in high doses can avoid respiratory failure in patients with Covid-19.
17-sept-20	European Respiratory Journal	Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	RCT	Iran	Edalatifard et al.	https://erj.ersjournals.com/content/early/2020/09/09/13993003.02808-2020	IRCT20200404046947N1	Methylprednisolone	Is methylprednisolone effective in treatment of COVID-19 patients?
17-sept-20	Plos Medicine	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)	Meta-analysis	Denmark	Juul et al.	https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003293	NA	NA	Effects of all treatment interventions for COVID-19
04-sept-20	The Lancet	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	CT	Russia	Logunov et al.	https://www.sciencedirect.com/science/article/pii/S0140673620318663?via%3Dihub	NCT04436471 and NCT04437875	vaccine	Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine
01-oct-20	International Journal of Antimicrobial Agents	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial	RCT	Iran	Sekhavati et al.	https://www.sciencedirect.com/science/article/pii/S0924857920303411?via%3Dihub	NA	azithromycine	Can therapy with HCQ+AZM reduce the hospital length of stay in COVID-19 patients?
10-sept-20	JAMA	Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial	RCT	China	Cheng et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680	ChiCTR2000030007	G-CSF	Do increased peripheral blood leukocyte and lymphocyte cell counts lead to clinical improvement in patients with COVID-19?
04-sept-20	The Lancet	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial	RCT	Brazil	Furtado et al.	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931862-6	NCT04321278	azithromycine	Would azithromycine improve clinical outcomes to COVID-19 patiets?
03-sept-20	Journal Genenral Internal Medicine	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis	Systematic review	India	Arunmozhimaran Elavarasi, et al.	https://link.springer.com/article/10.1007/s11606-020-06146-w	NA	Chloroquine, hydroxychloroquine	Is the use of CQ or HCQ effective and safe in reducing mortality and improving the clinical course, fever remission, and virologic clearance in COVID-19 patients?

November - December 2020	Diabetes & Metabolic Syndrome: Clinical Research & Reviews	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials"	Systematic review	India	Pathak et al.	https://www.sciencedirect.com/science/article/pii/S1871402120303362?via%3Dihub	NA	hydroxychloroquine	Is HCQ effective in milde to moderate COVID-19 patients?
06-sept-20	Naunyn-Schmiedeberg 's Archives of Pharmacology	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis	Systematic review	China	Zang et al	https://link.springer.com/article/10.1007%2Fs00210-020-01964-5	NA	hydroxychloroquine	Benefits and harms of HCQ in COVID-19 patients
02-sept-20	JAMA	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial	RCT	Brazil	Bruno M. Tomazini, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770277?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17021	NCT04327401	Dexamethasone	To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19–associated ARDS.
02-sept-20	JAMA	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis	Meta-analysis	International Collaboration	Jonathan A.C., et al.	https://jamanetwork.com/journals/jama/fullarticle/2770279?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17023	PROSPERO database (CRD42020197242)	Corticosteroids	To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
02-sept-20	JAMA	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 - A Randomized Clinical Trial	RCT	France	Pierre-François Dequin, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770276?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.16761	NCT02517489	Hydrocortisone	Does low-dose hydrocortisone decrease treatment failure in patients with COVID-19–related acute respiratory failure?
02-sept-20	JAMA	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	RCT	UK	Derek C. Angus, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770278?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17022	NCT02735707	Hydrocortisone	To determine whether hydrocortisone improves outcome for patients with severe COVID-19.
12 October 2020	BMJ	Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)	RCT	India	Anup Agarwal et al. and PLACID Collaborators	https://www.bmj.com/content/371/bmj.m3939	CTRI/2020/04/024775	Convalescent plasma	To assess the effectiveness of Convalescent plasma for the treatment of COVID-19
01-sept	MedRxiv	Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial	RCT	Spain	Avendaño-Solà et al.	https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v3.full.pdf	NCT04345523	Convalescent plasma	To demonstrate the efficacy and safety of Convalescent Plasma used to prevent progression to severe disease or death in hospitalized patients with earlier forms of COVID-19
09-sept	MedRxiv	Early viral clearance among COVID-19 patients when gargling with Povidone-Iodine and Essential oils - a clinical trial.	RCT	Malaysia	Nurul Azmawati Mohamed et al.	https://www.medrxiv.org/content/10.1101/2020.09.07.20180448v1.full.pdf	NCT04410159	Gargling with 1% povidone-iodine (Betadine®), essential oils (Listerine®) or tap water	To assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx.
12/09/2020	MedRxiv	Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia	RCT	USA	Rosas et al.	https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2.full.pdf	NCT04320615	Tocilizumab	To investigate whether tocilizumab has clinical benefit in hospitalized patients with severe COVID-19 pneumonia.
08-sept	Engineering	Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial	RCT	China	Wu et al.	https://www.sciencedirect.com/science/article/pii/S2095809920302411?via%3Dihub	ChiCTR2000030001	Triazavirin	To assess the efficacy of Triazavirin (TZV) for Covid-19
10-sept	BMC Infectious Diseases.	Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial.	RCT	Cuba	Delgado-Enciso et al.	https://assets.researchsquare.com/files/rs-68403/v1/e14a5067-cd36-4094-9c29-4bb66ac46805.pdf	RPCEC00000309	neutral electrolyzed saline	To evaluate the efficacy of treatment with intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19.
01-sept-20	Computers in Biology and Medicine	Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial	RCT	USA	Burdick et al.	https://www.sciencedirect.com/science/article/pii/S0010482520302845?via%3Dihub	NCT04390516	NA	NA
19-août-20	Journal of Medical Virology	Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis	Review	China	Jiang et al.	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26443	NA	Remdesivir	Remdesivir and its clinical effect

19-août-20	Journal of Antimicrobial Chemotherapy	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	RCT	Iran	Sadeghi et al.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa334/5889948	IRCT20200128046294N2	sofosbuvir/daclatasvir	IS sofosbuvir and dalatasvir effective in COVID patients?
18-août-20	Stem Cell Research & Therapy	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells	RCT	China	Shu et al.	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	ChiCTR2000031494	umbilical cord mesenchymal stem cells	Are human umbilical cord mesenchymal stem cell infusion effective and safe for the treatment of severe COVID?
October	Journal of Steroid Biochemistry and Molecular Biology	"Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study	RCT	Spain	Marta Entrenas Castillo, et al.	https://www.sciencedirect.com/science/article/pii/S0960076020302764?via%3Dihub	NCT04366908	Calcifediol	Evaluate the effect of calcifediol on ICU admission and mortality among patients hospitalized for COVID-19
13 August 2020	JAMA	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials	Vaccine - Phase I and II	China	Shengli Xia, et al.	https://jamanetwork.com/journals/jama/fullarticle/2769612	ChiCTR2000031809	Inactivated vaccine	To assess the safety and immunogenicity of this whole virus inactivated vaccine
21 August 2020	JAMA	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19	RCT	USA	Christoph D. Spinner, et al.	https://jamanetwork.com/journals/jama/fullarticle/2769871	NCT04292730	Remdesivir	Effect of remdesivir in patients with moderate COVID19
30 July 2020	BMJ	Drug treatments for covid-19: living systematic review and network meta-analysis	Systematic Review	International Collaboration	Reed AC Siemieniuk, et al.	https://www.bmj.com/content/370/bmj.m2980	NA	All treatments	Living systematic review and network meta-analysis
28-août	MedRXiv	RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study	RCT	USA/ Germany	Walsh et al.	https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2.full.pdf	NCT04368728	Vaccine: RNA vaccines BNT162b1 and BNT162b2	To assess the safety and immunogenicity of varying dose levels of vaccines BNT162b1 and BNT162b2.
12 August 2020	Clinical Infectious Diseases	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial	RCT	Brazil	Christiane Maria Prado Jeronimo, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816	NCT04343729	Methylprednisolone	Assess the efficacy of short-term methylprednisolone in patients with COVID-19
09 August 2020	Clinical Infectious Diseases	AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial	RCT	Russia	Andrey A. Ivashchenko, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024	NCT04434248	Favipiravir	Assess the efficacy and safety of favipiravir in moderate COVID19 and select the optimal dosing regimen for further evaluation (Phase III).
Preprint	International Journal of Infectious Diseases	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial		China	Fang Zheng, et al.	https://www.sciencedirect.com/science/article/pii/S120197122030597X?via%3Dihub	ChiCTR2000029496	Novaferon	Efficacy of Novaferon and Novaferon + Lopinavir/ritonavir in moderate and severe COVID19.
Preprint	medRxiv	Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.	RCT	Argentina	Mariano Duarte, et al.	https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2	NCT04355936	Telmisartan	Assess the anti-inflammatory effect of telmisartan in COVID-19 patients
14 August 2020	Critical Care	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial	RCT	USA	Joseph Miller, et al.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03220-x	NCT04345614.	Auxora	Safety and tolerability of auxora in severe or critical COVID-19
Preprint	medRxiv	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial	Phase II vaccine RCT	China	Yanjun Zhang, et al.	https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1	NCT04352608	Inactiviated Vaccine	Is this SARS CoV 2 inactivated vaccine safe and well tolerated?
Preprint	medRxiv	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial	RCT	Brazil	Maria IF Lopes, et al.	https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2	RBR-8jyhxh	Colchicine	To evaluate the efficacy of colcihcine in treating severe and moderate COVID-19
2 September 2020	NEJM	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	Phase I vaccine RCT	Australia	Cheryl Keech, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2026920	NCT04368988	NVX-CoV2373; recombinant nanoparticle vaccine	Assess the safety and tolerability of the NVX-COV2373 recombinant vaccine in healthy subjects.
23 July 2020	NEMJ	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19	RCT	Brazil	Alexandre B. Cavalcanti, et al.	https://www.nejm.org/doi/10.1056/NEJMoa2019014	NCT04322123	Hydroxychloroquine	Asses the efficacy of hydroxychloroquine with and without azithromycin in mild to moderate COVID19
6 July 2020	Journal of Medical Virology	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection	Systematic review	USA	Viveksandeep Thoguluva Chandrasekar, et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26302	NA	Hydroxychloroquine, Tocilizumab, Remdesivir, convalescent plasma, steroids, lopinavir/ritonavir	Asses overall efficacy of treatments that have been studied thus far.
Preprint	medRxiv	Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19	CT	Cuba	Yayquier Díaz, et al.	https://www.medrxiv.org/content/10.1101/2020.07.24.20153833v1	RPCEC00000311	Itolizumab	Is itolizumab a safe and efficient treatment for COVID 19 in elderley patients?
Preprint	medRxiv	Efficacy and tolerability of bevacizumab in patients with severe Covid -19	CT	China, Italy	Jiaojiao Pang, et al	https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1	NCT04275414	Bevacizumab	Is bevacizumab a safe and efficient treatment for severe COVID 19?
29 July 2020	EClinicalMedicine (Lancet)	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19	CT	China + USA	Weihui et al.	https://www.sciencedirect.com/science/article/pii/S2589537020302224	ChiCTR2000030262	IFN-κ plus trefoil factor 2	To evaluate the efficacy and safety of intranasal inhalation of TFF2 and IFN-κ protein for SARS-CoV-2 infection

21 July 2020	Virologica Sinica	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial	CT	China	Hu et al.	https://link.springer.com/article/10.1007%2Fs12250-020-00258-7	ChiCTR 2000030058	leflunomide	Is leflunomide effective in COVID-19 patients?
20-juil	Lancet	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	RCT	UK	Folegatti et al. on behalf of the Oxford COVID Vaccine Trial Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext	ISRCTN 15281137; NCT04324606	ChAdOx1 nCoV-19 vaccine	To assess the immunogenicity, reactogenicity, and safety of vaccination with ChAdOx1 nCoV-19 in single-dose and two-dose regimens.
20-juil	Lancet	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	RCT	China	Feng-Cai Zhu et al.	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6	NCT04341389	adenovirus type-5 (Ad5)-vectored COVID-19 vaccine	Phase 2 trial to further evaluate the immunogenicity and safety in a larger population, and to determine an appropriate dose for the efficacy study
12 August 2020	Nature	Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults	Phase 1/2 trial	USA/Germany	Mulligan et al.	https://www.nature.com/articles/s41586-020-2639-4	NCT04368728	RNA Vaccine BNT162b1	To assess safety, tolerability, and immunogenicity of RNA Vaccine candidate in a dose escalation study among healthy adults.
20-juil-20	Medrxiv	Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine	Phase 1/2 trial	Germany/ USA	Sahin et al.	https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf	NCT04380701, EudraCT: 2020-001038-36	RNA Vaccine BNT162b1	To complement previous reported data by providing a detailed characterisation of antibody and T76 cell immune responses elicited by BNT162b1 vaccination.
14-juil	NEMJ	An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	Phase 1 trial	USA	Jackson et al.	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483	NCT04283461	mRNA-1273 vaccine	To evaluate the safety and immunogenicity of mRNA-1273 vaccine
08-oct	NEJM	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.	RCT	UK	Horby et al. (RECOVERY Collaborative Group)	https://www.nejm.org/doi/10.1056/NEJMoa2022926	ISRCTN 50189673, NCT04381936	Hydroxychloroquine	To assess the safety and efficacy of hydroxychloroquine in patients hospitalized with COVID-19
10-juil	Medrxiv	A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)	RCT & retrospective cohort study	Taiwan	Cheng-Pin Chen et al.	https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1.full.pdf	NCT04384380	Hydroxychloroquine	To evaluate HCQ efficacy and tolerability in adult patients with mild to moderate COVID-19.
16-juil	Annals of Internal Medicine	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 - A Randomized Trial	RCT	USA	Skipper et al.	https://www.acpjournals.org/doi/10.7326/M20-4207	NCT04308668	Hydroxychloroquine	To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients
Preprint	Lancet	Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial	RTC	Spain	Mitjà et al,	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3615997	NCT04304053	Hydroxychloroquine, Darunavir, Cobicistat	Is early treatment with hydroxychloroquine (HCQ) with our without cobicistat/darunavir more efficacious than no-treatment for outpatients with mild Covid-19?
Preprint	ResearchSquare	A pragmatic randomized controlled trial reports the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics	RCT	Norway	Magnus Nakrem Lyngbakken, et al.	https://assets.researchsquare.com/files/rs-44055/v1/3fb11155-d83c-48a0-ae74-b3cce9a5eac3.pdf	NCT04316377	Hydroxychloroquine	To assess the effcacy and safety of hydroxychloroquine therapy on SARS-CoV-2 oropharyngeal viral kinetics in patients hospitalized with moderately severe COVID-19.
11 June 2020	Open Forum Infectious Diseases	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19	RCT	China	Jun Chen, et al.	https://pubmed.ncbi.nlm.nih.gov/32671131/	NCT04252274	Darunavir, Cobicistat	Evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) for treating mild COVID-19
15-juil-20	SN Comprehensive Clinical Medicine	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials	Systematic review & Meta-analysis	USA	Juan A. Siordia Jr et al.	https://link.springer.com/article/10.1007%2Fs42399-020-00399-6	N/A	lopinavir/ritonavir; arbidol; hydroxychloroquine; remdesivir; tocilizumab; favipiravir; heparin; dexamethasone	To assess the current evidence regarding human controlled COVID-19 treatment trials.
Preprint	BMC Infectious Diseases	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.	RT	Bangladesh	Abu Taiub Mohammed Mohiuddin Chowdhury, et al.	https://www.researchgate.net/profile/Abu_Taiub_Mohammed_Mohiuddin_Chowdhury2/publication/342159343_A_comparative_observational_study_on_Ivermectin-_Doxycycline_and_Hydroxychloroquine-Azithromycin_therapy_on_COVID19_patients/links/5f02954c92851c52d619d95e/A-comparative-observational-study-on-Ivermectin-Doxycycline-and-Hydroxychloroquine-Azithromycin-therapy-on-COVID19-	NCT04434144	Ivermectin, Doxycycline, Hydroxychloroquine, Azithromycin	Compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease.
updated 12/10/20	Cochrane	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review	Systematic review	International Collaboration	Piechotta V, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/abstract	NA	Convalescent plasma, hyperimmune immunoglobulin	Assess the effectiveness of convalescent plasma and hyperimmune immunoglobulin for treating people with COVID19

Preprint	Advanced Science	A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study	RCT	China	Zhigang Ren, et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202001435	ChiCTR2000029853	Azvudine	Efficacy of azvudine in treating mild COVID19 patients
24/06/2020	JAMA Network Open: Infectious Diseases	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial	Randomized clinical trial	Greece	Deftereos et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593	NCT04326790	Colchicine	To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with COVID-19.
30-juin-20	The International Journal of Clinical Practice	Febuxostat Therapy in Outpatients With Suspected COVID-19: A Clinical Trial	RCT	Iran	Davoodi et al.	https://pubmed.ncbi.nlm.nih.gov/32603531/	IRCT20190727044434N1	Hydroxychloroquine, febuxostat	Is febuxostat effective in comparision with hydroxychloroquine?
17 July 2020	NEMJ	Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report	RCT	UK	Horby et al. (RECOVERY Writing Committee)	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?casa_token=H8GAcaEgprUAAAAA:m_9Qlb5FCP6d6YPLPMryKLqVP0QTUouiQsD39ki_1j8u1syZDvAET7pLjZ3GbCpQSV4V62JZ8086BOdT	ISRCTN 50189673, NCT04381936	Dexamethasone	To test the effectiveness of dexamethasone in patients hospitalized with COVID-19
18-juin	medRxiv	GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia	RCT	Spain	Corral-Gudino et al.	https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1.full.pdf	EudraCT number: 2020-001934-37	methylprednisolone	To determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS)
05-juin-20	Science Immunology	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19	RCT	USA	Roschewski et al.	https://immunology.sciencemag.org/content/5/48/eabd0110	NA	Acalabrutinib	Is acalabrutinib effective in severe COVID-19 patients?
8 June 2020 - Accelerated publication	Nature	Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe	Modelling	UK	Seth Flaxman, et al.	https://www.nature.com/articles/s41586-020-2405-7	NA	Non-pharmaceutical interventions	Were the non-pharmaceutical interventions implemented in European countries effective in limiting the spread of SARS CoV-2?
8 May 2020	Nature - Leukemia	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation	Retrospective analysis	Germany	F. La Rosée, et al.	https://www.nature.com/articles/s41375-020-0891-0		Ruxolitinib	Efficacy and safety of ruxolitinib in severe COVID19
8 June 2020	Lancet Reheumatology	Canakinumab in a subgroup of patients with COVID-19	Retrospective analysis	Italy	Claudio Ucciferri, et al.	https://www.sciencedirect.com/science/article/pii/S2665991320301673?via%3Dihub	NA	Canakinumab	Is canakinumab a safe and effective treatment against COVID19?
10-juin-20	BMJ	Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study	Observational study	China	Min Liu et al.	https://www.bmj.com/content/369/bmj.m2195	NA	NA	To examine the protective effects of appropriate personal protective equipment
02-juin-20	The Lancet Digital Healt	Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study	Modelling study	UK	Gavines et al.	https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30133-X/fulltext#%20	NA	NA	What is the impact of different control measures for mitigating the burden of COVID-19
01-juin-20	Journal of Clinical Microbiology	Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong	Diagnostic	Hong-Kong	Jonathan Hon-Kwan Chen	https://jcm.asm.org/content/early/2020/05/29/JCM.00936-20	NA	Nucleic acid test	Evaluation of Luminex NxTAG in COVID-19 detection
26-mai-20	Clinical Microbiology and Infection	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review	Systematic review / Meta-analysis	Australia/Sri Lanka	Rodrigo et al.	https://www.sciencedirect.com/science/article/pii/S1198743X20302937?via%3Dihub	NA	Hydroxychloroquine, chloroquine	Does hydroxychloroquine have antiviral effect?
14-juin	MedRxiv	Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests	Diagnostic	Belgium	Herroelen et al.	https://www.medrxiv.org/content/10.1101/2020.06.09.20124719v2.full.pdf	N/A	Antibody test	To test the performance characteristics of seven commercially available serology tests for detection of antibodies against the SARS-CoV-2
09-juin	MedRxiv	Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience	observational study	Cuba	Pereda et al.	https://www.medrxiv.org/content/10.1101/2020.05.29.20109199v1.full.pdf	RPCEC00000318	Interferon alpha 2b	To assess the therapeutic efficacy of IFN-α2b in patients infected with SARS-CoV-2
10-juin	MedRxiv	ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19	Retrospective analysis	USA	Cepelowicz Rajter et al.	https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.full.pdf	N/A	Ivermectin	To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19
14-juin	MedRxiv	First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia	prospective study with FDA emergency use IND	USA	Temesgen et al.	https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2.full.pdf	N/A	Lenzilumab	To assess the efficacy of lenzilumab therapy in patients hospitalized with severe COVID-19 pneumonia, who had clinical and/or biomarker evidence for increased risk of progression to respiratory failure.
02-juin	MedRxiv	Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study	prospective cohort study	Denmark/USA	Eugen-Olsen et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20114678v1.full.pdf	N/A	Prognostic biomarker	To investigate whether soluble urokinase plasminogen activator receptor (suPAR) can aid in identifying patients with low risk of respiratory failure when presenting with symptoms of COVID-19.

08/06/2020	MedRxiv	Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial	CT	USA	Hess et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20116988v1.full.pdf	NCT: 04366791	Low dose radiation	To determine if Low Dose-Radiation Therapy can reduce pulmonary inflammation associated with COVID-19 pneumonia.
02-juin	MedRxiv	Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study	CT	China	Wang et al.	https://www.medrxiv.org/content/10.1101/2020.05.29.20114223v1.full.pdf	ChiCTR2000030058	Leflunomide	To evaluate the safety and efficacy of leflunomide for the treatment of refractory COVID-19 in adult patients.
08-juin	MedRxiv	Nano short peptide nutrition intervention on the prognosis of patients with COVID-19	Retrospective analysis	China	Zhang et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20083980v1.full.pdf	N/A	enteral nutrition	To explore the effect of high fiber whey short peptide enteral nutrition on the prognosis of patients with COVID-19
05-juin	MedRxiv	Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study	prospective cohort study	Spain/ USA/Canada	Hernández et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117994v1.full.pdf	N/A	Ozone therapy	To determine if ozonated autohemotherapy is associated with a shorter time to clinical improvement in patients with severe COVID-19 pneumonia.
02-juin	MedRxiv	CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients	CT	Cuba	Venegas-Rodriguez et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1.full.pdf	RPCEC00000313	CIGB-258 immuno-modulatory peptide	To determine the effect of Center for Genetic Engineering and Biotechnology (CIGB)-258 therapy in seriously, or critically ill patients with COVID-19.
02-juin	MedRxiv	A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients.	Observational study	Singapore	Chuen Wen Tan et al.	https://www.medrxiv.org/content/10.1101/2020.06.01.20112334v1.full.pdf	N/A	Vitamin D, Magnesium and Vitamin B12 (DMB)	To determine the clinical outcomes of older COVID-19 patients who received Vitamin D, Magnesium and Vitamin B12 (DMB) compared to those who did not
03-juin	MedRxiv	Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients	Retrospective analysis	USA	Trinh et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20117929v1.full.pdf	N/A	anticoagulation agents	To evaluate differences in morbidity and mortality among mechanically ventilated patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation
21 October 2020	Journal of Translational Medicine	Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial	CT	Italy	Perrone et al.	https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02573-9	EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)	Tocilizumab	To evaluate efficacy of tocilizumab in COVID-19 pneumonia patients.
02/06/2020	MedRxiv	Rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical trial and implementation study	prospective clinical trial and observational study	UK/South Africa	Dami Collier, et al.	https://www.medrxiv.org/content/10.1101/2020.05.31.20114520v1.full.pdf	NCT04326387	Nucleic acid diagnostic	To compare SAMBA II SARS-CoV-2 performance against the standard lab RTPCR test in suspected COVID-19 cases presenting to hospital, followed by a hospital-based implementation study.
06-juin	MedRxiv	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity	Diagnostic comparison	Austria	Perkmann et al.	https://www.medrxiv.org/content/10.1101/2020.06.04.20117911v2.full.pdf	N/A	Antibody diagnostic	To compare three fully automated large-scale laboratory analyzer test systems, with particular emphasis on specificity, which is crucial for an adequate positive predictive value given the current low seroprevalence worldwide.
05-juin	MedRxiv	Implementation and evaluation of a novel real-time multiplex assay for SARS-CoV-2: In-field learnings from a clinical microbiology laboratory	Diagnostic validation study	Australia	Williams et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117267v1.full.pdf	N/A	Nucleic acid diagnostic	To describe initial experience using a commercially-available multiplex two-step nested tandem RT-PCR assay for the detection of coronaviruses that infect humans, including SARS-CoV-2
02-juin	MedRxiv	Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay	Diagnostic validation study	USA/Switzerland	Danh et al.	https://www.medrxiv.org/content/10.1101/2020.05.28.20105692v1.full.pdf	N/A	Diagnostic for indentifying suitable Convalescent plasma donors	To construct and validate a cell-free assay to measure neutralizing antibodies in order to identify suitable donors of convalescent plasma
02-juin	MedRxiv	Diagnostic accuracy of a host response point-of-care test for identifying COVID-19	diagnostic clinical evaluation	UK	Clark et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20114512v1.full.pdf	ISRCTN14966673	Diagnostic	To evaluate the real-world diagnostic accuracy of FebriDx for the identification of COVID-19 in hospitalised adults
August 2020	Journal of Clinical Virology	Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study	Diagnostic assay	Spain	García et al.	https://www.sciencedirect.com/science/article/pii/S1386653220302158?via%3Dihub	NA	NA	To analyze the diagnostic performance of one serologic rapid test in COVID-19 patients
06-juin-20	Brain, Behaviour and Imunity	Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study	Retrospective study	China	Zhang et al.	https://www.sciencedirect.com/science/article/pii/S0889159120309946	NA	NA	Effects of sleep quality on recovery from lymphopenia and clinical outcomes in hospitalized patients with COVID-19
28 May 2020	Drug Safety	- Remdesivir in Treatment of COVID 19: A Systematic Benefit–Risk Assessment	Systematic review	UK	Miranda Davies, et al.	https://doi.org/10.1007/s40264-020-00952-1	NA	Remdesivir	To assess the overall benefit–risk of the use of remdesivir as a treatment for COVID-19 compared with standard of care, placebo or other treatments
27 May 2020	Society of Critical Care	Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019	Observational study	USA	Thomas K. Maatman, et al.	DOI: 10.1097/CCM.0000000000004466	NA	Venous thromboembolism prophylaxis	To determine the frequency of venous thromboembolism (VT) in critically ill COVID19 patients who recieved prophylaxis for VT.
3 June 2020	JAMA	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 - A Randomized Clinical Trial	RCT	China	Ling Li, et al.	doi:10.1001/jama.2020.10044	ChiCTR2000029757	Convalescent Plasma	Is convalescent plasma a safe and efficient treatment for severe COVID19?
Preprint	Journal of the American College of Cardiology	Ramipril in High Risk Patients with COVID-19	Retrospective analysis	Spain	Ignacio J. Amat-Santos, et al.	https://www.sciencedirect.com/science/article/pii/S073510972035395X?via%3Dihub	NCT03201185 (source RCT)	Ramipril	To analyze if ramipril modifies the risk for COVID-19.

3 June 2020	PlosOne	The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness	Systematic review / Meta-analysis	Italy	Primiano Iannone, et al.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234025	NA	N95 respirators	Should health care workeers wear surgical masks or N95 respirators during the routine care (not involving aerosol generating procedures) of COVID-19 suspected or affected patients?
1 June 2020	Lancet	Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis	Systematic review	International collaboration	Derek K Chu, et al.	https://doi.org/10.1016/S0140-6736(20)31183-1	PROSPERO: CRD42020177047	PPE	Investigate the effects of physical distance, face masks, and eye protection on virus transmission in health-care and non-health-care (eg, community) settings
Preprint	Diabetes, obesity & metabolism	Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study	Case population study	Italy	Gian Paolo Fadini, et al.	https://pubmed.ncbi.nlm.nih.gov/32463179/	NA	DPP-4 inhibitors	Do DPP-4 inhinbitors have a protective effect agains COVID19?
03 June 2020	NEJM	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	RCT	USA / Canada	D.R. Boulware, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2016638	NCT04308668.	Hydroxychloroquine	Is hydroxychloroquine effective in post-exposure prohylaxis therapy?
Preprint	Biosensors and Bioelectronics	Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis	Diagnostic assay	USA	Zhen Huang, et al.	https://doi.org/10.1016/j.bios.2020.112316	NA	CRISPR RT-PCR	Can CRISPR technology simplify RT-PCR for SARS CoV2 and be effective for diagnos?
Preprint	Gastroenterology	Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	Retrospective study	USA	Daniel E. Freedberg, et al.	https://www.gastrojournal.org/article/S0016-5085(20)34706-5/fulltext	NA	Famotidine	Do COVID19 patients taking famotidine have a lower risk of intubation and/or death?
27 May 2020	NEJM	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	RCT	International collaboration / Gilead Sciences	Jason D. Goldman, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2015301	NCT04292899	Remdesivir	Is a 5 day course of remedesivir as effective as a 10 course in treating moderately ill COVID19 patients?
22 May 2020	NEJM	Remdesivir for the Treatment of Covid-19 — Preliminary Report	RCT	International collaboration	J.H. Beigel, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	NCT04280705	Remdesivir	Is remdesivir an effective treatment for reducing time to recovery in COVID19 patients?
Preprint	Journal of Allergy and Clinical Immunology	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial	RCT	China	Yang Cao, et al.	https://doi.org/10.1016/j.jaci.2020.05.019	ChiCTR-OPN-2000029580.	Ruxolitinib	To evaluate the efficacy and safety of ruxolitinib for patients with severe COVID19.
Preprint	Clinical Infectious Diseases	Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID 19 by restoration of lymphocytopenia and reversion of exhausted T cells	Retrospective study	China	Yueping Liu, et al.	https://pubmed.ncbi.nlm.nih.gov/32442287/	NA	Thymosin alpha	Is thymosin alpha a safe and effective treatment for severe COVID19?
Preprint	International Journal of Infectious Diseases	HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS	Review	Australia	C Raina MacIntyre, et al.	https://www.sciencedirect.com/science/article/pii/S1201971220303994	NA	PPE	Level of protection confered by masks and respirators for common coronavirus.
29-mai-20	The Lancet Rheumatology	Anakinra for severe forms of COVID-19: a cohort study	Cohort study	France	Huet et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	NA	Anakinra	Use of anakinra in patients who were admitted to hospital for severe forms of COVID-19
22-mai-20	The Lancet	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	CT	China	Feng-Cai Zhu et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext	NCT04313127	Ad5 vectored COVID-19 vaccine	Are different doses of Ad5 vectored COVID-19 vaccine safe and immunogenic?
29-mai-20	Preprint	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Comparative study	China	Zhicheng Zhang et al.	https://www.researchsquare.com/article/rs-28376/v1.pdf	NA	Danopevir and lopinavir/ritonavir	Antiviral effect of danopevir or lopinavir/ritonavir in COVID-19 patients
01-juin-20	Current Medical Science	Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission–A Preliminary Report of a Retrospective Cohort Study	Observational study	China	Zhang et al.	https://link.springer.com/content/pdf/10.1007/s11596-020-2203-3.pdf	NA	Arbidol	Is Arbidol effective in profylaxis of COVID?
26-mai-20	Advanced Journal of Emergency Medicine	Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-label Single-Arm Clinical Trial	CT	Iran	Payandemehr et al.	http://ajem.tums.ac.ir/index.php/ajem/article/view/454/307	IRCT20150914024017N1	Interferon beta1a	Is interferon beta1a effective in treatment of COVID-19?
13 July 2020	Antiviral Agents	Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial	RCT	Iran	Davoudi-Monfared et al.	https://aac.asm.org/content/early/2020/07/08/AAC.01061-20	IRCT20100228003449N28	Interferon beta-1a	To evaluate efficacy and safety of IFN β-1a in patients with severe COVID-19.
30/05/2020	medRxiv	A serological assay to detect SARS-CoV-2 antibodies in at-home collected fingerprick dried blood spots	Clinical Evaluation of diagnostic test	USA	Karp et al.	https://www.medrxiv.org/content/10.1101/2020.05.29.20116004v2.full.pdf	IRB protocol #20180015	Antibody diagnostic test	To develop and clinically evaluate an at-home finger-prick dried blood spot test to detect SARS-CoV-2 antibodies
27/05/2020	medRxiv	Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2	Clinical Evaluation of diagnostic test	UK/USA/South Africa	Assennato et al.	https://www.medrxiv.org/content/10.1101/2020.05.24.20100990v2.article-info	N/A	Nucleic acid diagnostic test	To assess the analytical and clinical performance of the SAMBA II 83 SARS-CoV-2 Test using panels and clinical samples.
30/05/2020	medRxiv	EasyCOV : LAMP based rapid detection of SARS-CoV-2 in saliva	Clinical Evaluation of diagnostic test	France	L'Helgouach et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20117291v1.full.pdf	N/A	saliva RT-LAMP diagnostic test	To develop and clincally evaluate a new simple saliva SARS-CoV-2 detection test based on RT-LAMP technology
27/05/2020	medRxiv	Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgG Combined Antibody Tests	Clinical Evaluation of diagnostic test	France	Prazuck et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20112888v1.full.pdf	N/A	Antibody rapid diagnostic test	To evaluate the performance of two COVID 19 IgM/IgG Rapid Diagnostic Tests compared to the gold standard, RT-PCR.
29/05/2020	medRxiv	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial	proof of concept study	Italy	Perotti et al.	https://www.medrxiv.org/content/10.1101/2020.05.26.20113373v1.full.pdf	NCT 04321421	convalescent plasma	To show the potential efficacy and safety of hyperimmune plasma infusions, obtained from convalescent donors, in COVID-19 patients with respiratory failure

26/05/2020	medRxiv	Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19	Retrospective analysis	USA	Patel et al.	https://www.medrxiv.org/content/10.1101/2020.05.22.20109355v1.full.pdf		High Flow Nasal Therapy	To analyse the outcomes of COVID-19 patients with moderate-to-severe hypoxemic respiratory failure receiving High Flow Nasal Therapy
22-mai-20	The Lancet	Hydroxychloroquine or chloroquine with or without a with or without a macrolide for treatment of COVID-19: a multinational registry analysis	Observational study	USA/Switzerland	Mehra et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext	NA	Hydroxychloroquine	Are these treatment regimens associated with in-hospital death?
15 May 2020	Frontiers in Immunology	Interferon-a2b Treatment for COVID-19	CT	Canada, China	Qiong Zhou, et al.	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full	NA	Interferon-a2b	Is Interferon-a2b efficient in accelerating viral clearance and reducing inflammation markers?
19 May 2020	Clinical Infectious Diseases	Early Short Course Corticosteroids in Hospitalized Patients with COVID-19	Retrospective study	USA	Fadel et al.	https://www.medrxiv.org/content/10.1101/2020.05.04.20074609v1.full.pdf	NCT04374071	corticosteroids	To examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.
Preprint	medRxiv	Convalescent plasma treatment of severe COVID-19: A matched control study	CT	USA	Sean T. H. Liu, et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1	NA	Convalescent plasma	Is convalescent plasma an effective treatment for severe COVID19?
14 May 2020	Lancet	Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	Case population study	Spain	Francisco J de Abajo, et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext	EUPAS34437	renin–angiotensin–aldosterone system inhibitors, RAAS	Does use of RAAS predispose patients to severe COVID19?
Preprint	Cardiology Journal	Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial	Randomized crossover trial	Poland	Marek Malysz, et al.	https://journals.viamedica.pl/cardiology_journal/article/view/68336	NA	PPE	To evaluate various methods of chest compressions in patients with suspected/confirmed SARS-CoV-2 infection conducted by medical students wearing full personal protective equipment (PPE) for aerosol generating procedures (AGP).
15 May 2020	NEJM	Compassionate Use of Remdesivir in Covid-19 (Grein et al. - NEMJ)	Letters to the editor	International	Stefano Bonovas, Gerd Fätkenheuer, Christian Hoffman, Jiayuan Wu	https://www.nejm.org/doi/full/10.1056/NEJMc2015312	NA	Remdesivir	Re-analysis of cumulative incidence of improvement, patient classification
Preprint	Clinical Microbiology and Infection	A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA	Diagnostic clinical evaluation	China	Ji Wang, et al.	https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2820%2930284-6	NA	Diagnostic test	To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA
Preprint	Journal of Clinical Virology	A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2	Diagnostic assay comparison	Canada	Jason J., et al.	https://www.sciencedirect.com/science/article/pii/S1386653220301840	NA	Oropharyngeal/nares and nasopharyngeal swabs	Are combined oropharyngeal/nares swab is a suitable alternative for nasopharyngeal swabs for COVID19 sample colleciton?
19 May 2020	Nature	Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	Diagnostic assay	Chinq	Xueyan Mei, et al.	https://www.nature.com/articles/s41591-020-0931-3	N/A	AI diagnostic algorithm	Can an AI model rapidly identify SARS-CoV-2 infection based on initial chest CT scans and associated clinical information of COVID-19 (+) patients in the early stage?
23-mai	Medrxiv	Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19	retrospective analysis	South Korea	Sang Youl Rhee et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20108555v1.full.pdf	N/A	dipeptidyl peptidase-4 (DPP-4i), renin–angiotensin system (RAS) blockade	To investigate the effects of dipeptidyl peptidase-4 (DPP-4i) and renin–angiotensin system (RAS) blockade on the short-term clinical outcomes of COVID-19
22-mai	Medrxiv	Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis?	prospective cohort study	France	Alanio	https://www.medrxiv.org/content/10.1101/2020.05.18.20105296v1.full.pdf	N/A	anti-Pneumocystis jirovecii prophylaxis	To investigate the prevalence of Pneumocystis jirovecii in COVID-19 patients admitted to the ICU
23/05/2020	Medrxiv	Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection	Diagnostic	China	Hu et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20108530v2	N/A	RT-LAMP Diagnostic test	To develop and validate a novel RT-LAMP assay capable of detecting SARS-CoV-2 RNA for potential use in centralized facilities and point-of-care settings
22 May 2020	Medrxiv	Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support	retrospective analysis	Italy, UK	Gritti et al.	https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v3.full.pdf	NCT04322188	siltuximab	Efficacy of siltuximab for treatment of severe patients with COVID-19
22-mai	Medrxiv	Almitrine as a non ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients	Case control series	France	Losser et al.	https://www.medrxiv.org/content/10.1101/2020.05.18.20105502v1.full.pdf	N/A	Almitrine	To test if intravenous almitrine can improve hypoxia in mechanically ventilated COVID-19 patients.
12-mai	MedRxiv	Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment	Systematic benefit-risk assessment	UK	Davies et al.	https://www.medrxiv.org/content/10.1101/2020.05.07.20093898v1.full.pdf	N/A	Remdesivir	To examine the benefit-risk profile of remdesivir in COVID-19 patients compared to standard of care, placebo or other treatments.
15-mai	MedRxiv	Assisting Scalable Diagnosis Automatically via CT Images in the Combat against COVID-19	Application of deep learning to retrospective analysis	China	Liu et al.	https://www.medrxiv.org/content/10.1101/2020.05.11.20093732v1.full.pdf	N/A	Chest CT	To test the hypothesis that application of deep learning to 3D chest CT images could help identify COVID-19 infections.
15-mai	MedRxiv	The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents	retrospective analysis	Belgium	De Spiegeleer et al.	https://www.medrxiv.org/content/10.1101/2020.05.11.20096347v1.full.pdf	N/A	ARBs, ACEi, Statins	To explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes.

14-mai	MedRxiv	Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients	expanded access program	USA	Joyner et al.	https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf	NCT04338360	Convalescent plasma	To analyse key safety metrics following transfusion of convalescent plasma in patients with severe or life-threatening COVID-19
15-mai	MedRxiv	Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series	retrospective case study	USA	Weber et al.	https://www.medrxiv.org/content/10.1101/2020.05.13.20087734v1.full.pdf	NCT04387786	Nebulized in-line endotracheal Dornase Alfa	To report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for intubated and mechanically ventilated patients with COVID-19.
13-mai	MedRxiv	Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas	Case series	USA	Salazar et al.	https://www.medrxiv.org/content/10.1101/2020.05.08.20095471v1.full.pdf	N/A	Convalescent plasma	To determine if transfusion of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.
30 April 2020	Journal of Virus Eradication	A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?	Systematic review	UK	Victoria Pilkington, et al.	http://viruseradication.com/journal-details/A_review_of_the_safety_of_favipiravir_%E2%80%93_a_potential_treatment_in_the_COVID-19_pandemic%5E/	NA	Favipiravir	Safety of favipiravir
12 May 2020	Basic Research in Cardiology	Allogeneic cardiosphere derived cells (CAP 1002) in critically ill COVID 19 patients: compassionate use case series	Case series	USA	Siddharth Singh, et al.	https://link.springer.com/article/10.1007/s00395-020-0795-1	NA	CAP-1002	To evaluate the safety and impact of administration of allogeneic CDCs, formulated for intravenous (IV) infusion as CAP-1002, in critically ill COVID-19 patients.
Preprint	Canadian Medical Association Journal	Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis	Systematic Review ; Meta-analysis	International Collaboration	Zhikang Ye, et al.	https://www.cmaj.ca/content/cmaj/early/2020/05/14/cmaj.200645.full.pdf	NA	Corticosteroids	Assess efficacy and safety of corticosteroids for COVID19, SARS, MERS, CAP, ARDS and influenza
1 May 2020	Clinical and Experimental Rheumatology	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19	CT	Italy	S. Sciascia, et al.	https://www.clinexprheumatol.org/abstract.asp?a=15723	NA	Tocilizumab	To assess the efficacy and safety of tocilizumab in severe COVID19 patients
23 April 2020	BMJ Global Health	Facial protection for healthcare workers during pandemics: a scoping review	Scoping Review	USA	Laura R Garcia Godoy, et al.	https://gh.bmj.com/content/5/5/e002553	NA	Facial protection	Efficacy of different facial protection devices, especially in light of N95 respirator shortages
Preprint	Pharmacological Research	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post treatment hospitalisation status	Case series	Italy	Spinello Antinori, et al.	https://pubmed.ncbi.nlm.nih.gov/32407959/	NA	Remdesivir	Comparative efficacy of remdesivir in ICU and non-ICU patients
15 April 2020	Cochrane Library	Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff	Systematic Review	International Collaboration	Verbeek JH, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011621.pub4/full	NA	PPE	To evaluate which type of full-body PPE and which method of donning or do.ing PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols.
14 May 2020	Cochrane Library	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review	Systematic Review	Netherlands	Valk SJ, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600/full	NA	Convalescent Plasma	To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is eJective and safe in the treatment of people with COVID-19.
Preprint	Journal of Allergy and Clinical Immunology	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease	Case series	Italy	Emanuele Pontali, et al.	https://www.jacionline.org/article/S0091-6749(20)30634-5/fulltext	NA	Anakinra	Preliminary assessment of the safety and efficacy of anakirna in severe/moderate COVID19
09 May 2020	Microorganisms	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results From SMAtteo COvid19 REgistry (SMACORE)	Observational study	Italy	Colaneri et al.	https://pubmed.ncbi.nlm.nih.gov/32397399/	NA	tocilizumab	What is the role of tocilizumab therapy in severe COVID-19 patients?
14 May 2020	BMJ	Hydroxychloroquine in Patients With Mainly Mild to Moderate Coronavirus Disease 2019: Open Label, Randomised Controlled Trial	RCT	China	Tang et al.	https://www.bmj.com/content/369/bmj.m1849.long	ChiCTR2000029868	Hydroxychloroquine	Is hydroxychloroquine effective and safe in COVID-19 patients?
05 May 2020	BMJ	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data	Observational study	France	Mahévas et al.	https://www.bmj.com/content/369/bmj.m1844	NA	Hydroxychloroquine	Is hydroxychloroquine effective?
08 May 2020	MedRxiv	Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients	Clinical Evaluation of diagnostic test	France	Tuaillon et al.	https://www.medrxiv.org/content/10.1101/2020.05.04.20090027v3.full.pdf	NCT04347850	Antibody diagnostic test	To assess and compare the performance of 6 rapid tests and 3 ELISAs for the diagnosis of COVID-19, and to explore seroconversions in subjects with confirmed COVID-19
08 May 2020	MedRxiv	ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens	Clinical evaluation of diagnostic test	China	Suo et al.	https://www.medrxiv.org/content/10.1101/2020.02.29.20029439v2.full.pdf		PCR diagnostic test	To compare the dynamic range and the limit of detection (LoD) between ddPCR and RT-PCR
05 May 2020	MedRxiv	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial	RCT	China	Yan Lou et al.	https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1.full.pdf	ChiCTR2000029544	baloxavir marboxil, favipiravir	To evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard antiviral treatment
11 May 2020	MedRxiv	Celebrex adjuvant therapy on COVID-19: An experimental study	Clinical trial	China	Wenxin Hong et al.	https://www.medrxiv.org/content/10.1101/2020.05.05.20077610v1.full.pdf	ChiCTR2000031630	Celebrex (Celecoxib)	To determine if excessive PGE2 may be a key in the pathology of COVID-19 and whether COX-2 is a critical target for therapy.

05 May 2020	MedRxiv	COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective?	retrospective analysis of International mortality rates	Mexico	Paredes et al.	https://www.medrxiv.org/content/10.1101/2020.05.01.20087411v1.full.pdf	N/A	BCG	To take into account the possible confounders when analyzing the difference in mortality rates between countries with and without history of a universal BCG vaccination program.
08 May 2020	MedRxiv	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients	retrospective observational study	USA	Carlucci et al.	https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1.full.pdf	N/A	zinc sulfate (as add-on therapy to hydroxychloroquine and azithromycin)	To determine if zinc sulfate added to hydroxychloroquine and azithromycin may improve outcomes among hospitalized patients.
05 May 2020	MedRxiv	Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis	Systematic review and meta-analysis	China	Liang et al.	https://www.medrxiv.org/content/10.1101/2020.04.03.20051649v3.full.pdf	N/A	facemask	To evaluate the effectiveness of the use of masks to prevent laboratory-confirmed respiratory virus transmission.
5 May 2020	Nature	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis	Meta-analyisis	China	Huan Li, et al.	https://www.nature.com/articles/s41375-020-0848-3.pdf	NA	Corticosteroids	Evaluate the safety and efficacy of corticosteroids on SARS-CoV-2, SARS-CoV, and MERS-CoV infections
Preprint	Journal of Biomedical and Health Informatics	In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform	Giulia Russo, et al.	Italy	Giulia Russo, et al.	https://www.biorxiv.org/content/10.1101/2020.05.06.080630v1.full.pdf	NA	Vaccine	Can an efficient in-silico trial base be developed, and can it evaluate vaccine candidates?
Preprint	Nature	Effect of non-pharmaceutical interventions to contain COVID-19 in China	Mathematical Modeling	China, UK, US	Shengjie Lai, et al.	https://www.nature.com/articles/s41586-020-2293-x_reference.pdf	NA	Non-pharmaceutical interventions	Were non-pharmaceutical interventions effective in reducing the number of cases and speed of the epidemic in mainland China?
29 April 2020	Autoimmunity Reviews	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	Retrospective analysis	Israel	Omer Gendelman, et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406/	NA	Colchicine, hydroxychloroquine	Protective role of colchicine or hydroxychloriquine for COVID19 infection
Preprint	Autoimmunity Reviews	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	Observational study	Italy	Paola Toniati, et al.	https://www.sciencedirect.com/science/article/abs/pii/S1568997220301300	NA	Tocilizumab	Is tocilizumab effective for improving respiratory condition in severe COVID19?
April 29 2020	PNAS	Effective treatment of severe COVID-19 patients with tocilizumab	Retrospective analysis	China	Xiaoling Xua, et al.	https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf		Tocilizumab	Efficacy and safety of tocilizumab in sever COVID19
08 May 2020	The Lancet	Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	RCT	Hong Kong	Hung et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext	NCT04276688	interferon beta-1b, lopinavir–ritonavir, ribavirin	The efficacy and safety of combination
07 May 2020	The Lancet Rheumatology	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	Observational study	Italy	Cavalli et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	NCT04318366	anakinra	Efficacy of anakinra
19 April 2020	Journal of Clinical Virology	Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review	Systematic Review	USA	Alzghari et al.	https://www.sciencedirect.com/science/article/pii/S1386653220301220?via%3Dihub	NA	NA	Outcomes associated with TCZ treatment in patients with COVID-19
25 April 2020	Clinical Microbiology and Infection	Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study	Retrospective CT	China	N. Lian, et al.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30234-2/fulltext	NA	Umifenovir (Arbidol)	Effectiveness and safety of umifenovir for moderate COVID-19
16 April 2020	Journal of Infection	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	CT	Italy	Fabrizio Cantini, et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/	NA	Baricitinib	Is Baricitinib an effective drug for clinical and respiratory improvement in moderate COVID19 patients?
04 May 2020	medRxiv	Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19	growth curve analysis	USA	Berg et al.	https://www.medrxiv.org/content/10.1101/2020.04.05.20054163v5.full.pdf	N/A	BCG vaccination	Does BCG vaccination serve as a protective factor against COVID-19
22 April 2020	medRxiv	Does TB Vaccination Reduce COVID-19 Infection? No Evidence from a Regression Discontinuity Analysis	regression analysis based on observational data	USA/ Japan	Fukui et al.	https://www.medrxiv.org/content/10.1101/2020.04.13.20064287v1.full.pdf	N/A	BCG vaccination	To assess the effectiveness of BCG vaccination against COVID-19
29 April 2020	medRxiv	A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19	RCT	China	Fang Zheng et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1.full.pdf	ChiCTR2000029496	Novaferon, Lopinavir/Ritonavir	To determine the antiviral effects of Novaferon for COVID-19
01 May 2020	medRxiv	Review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease (COVID-19) globally.	Systematic review	Greece, France	Fragkou et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20080226v1.full.pdf	N/A	all treatment and preparation options for covid-19	To summarise the data on all currently tested treatment and prevention options for COVID-19, and to methodologically analyse and evaluate the quality of the registered interventional studies
01 May 2020	medRxiv	Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19	retrospective analysis	China	Bo Yu et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1.full.pdf	N/A	Hydroxychloroquine	Could hydroxychloroquine administration be beneficial in the treatment of critically ill patients with COVID-19?
29 April 2020	medRxiv	Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19	retrospective analysis	USA	Ip et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.20077388v1.full.pdf	N/A	anti-hypertensive agents	To determine if anti-hypertensive drugs are harmful or beneficial to Covid-19 patients with hypertension

29 April 2020	medRxiv	Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study	retrospective analysis	China	Xiu Lan et al.	https://www.medrxiv.org/content/10.1101/2020.04.25.20079079v1.full.pdf	N/A	lopinavir/ritonavir, arbidol	To evaluate the antiviral efficacy of lopinavir/ritonavir alone or combined with arbidol in the treatment of hospitalized patients with COVID-19.
04 May 2020	medRxiv	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19	prospective observational study	China	Mingxing Huang et al.	https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf	(ChiCTR2000029609	Chloroquine	To assess the efficacy and safety of chloroquine with different doses in COVID-19
01 May 2020	medRxiv	QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin	retrospective analysis	USA/Italy	Chorin et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20074583v1.full.pdf	N/A	Hydroxychloroquine, Azithromycin	To evaluate the effects of Hydroxychloroquine/Azithromycin on the QT interval and the arrhythmic risk in patients with SARS-CoV-2 infection.
01 May 2020	medRxiv	Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits	diagnostic kit evaluation	China	David Surace Kapitula et al.	https://www.medrxiv.org/content/10.1101/2020.04.25.20080002v1.full.pdf	N/A	qPCR Diagnostic test	To assess and compare all nucleic acid-based COVID-19 testing kits from quality control perspectives
29 April 2020	medRxiv	Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review	Systematic review	USA/Canada	Michaud et al.	https://www.medrxiv.org/content/10.1101/2020.04.21.20066761v2.full.pdf	N/A	azithromycin, chloroquine, favipiravir, hydroxychloroquine, lopinavir/ritonavir, remdesivir	To determine the relative risk of drug-induced Long QT Syndrome (LQTS) associated with SARS-CoV-2 (COVID-19) proposed repurposed drugs compared to well-known torsadogenic compounds
29 April 2020	medRxiv	Concentration-dependent mortality of chloroquine in overdose	retrospective analysis, Bayesian logostic regression, pharmacodynamic modelling	Thailand/ UK/ France	Watson et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.20078303v1.full.pdf	N/A	Chloroquine	To evaluate the risk of overdose for chloroquine treatment or prevention regimens currently being trialled in COVID19
29 April 2020	The Lancet	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	RCT	China	Wang et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext	NCT04257656	remdesivir	Effect of remdesivir in COVID-19 patients
02 May 2020	Academic Emergency Medicine	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.	Systematic review	USA	Chowdhury et al.	https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.14005	NA	NA	Analyze current literature to find the role of CQ and HCQ
20 April 2020	medRxiv	Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study	retrospective cohort study	China	Ziyun Shao et al.	https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf	N/A	intravenous immunoglobulin (IVIG) therapy	To determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients.
22 April 2020	Clin Pharmacol Ther.	Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.	pharmacokinetic (PBPK) model	Netherlands	Verscheijden et al.	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1864	N/A	Chloroquine	To establish best-evidence to inform pediatric Chloroquine doses for children infected with COVID-19
24 April 2020	JAMA Network Open	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.	RCT	Brazil	Borba et al	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499	NCT04323527	Chloroquine	To evaluate the safety & efficacy of different dosages of chloroquine in patients with severe COVID-19.
21 April 2020	medRxiv	A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019（COVID-19）	RCT	China	Zhong et al.	https://www.medrxiv.org/content/10.1101/2020.04.15.20066266v1.full.pdf	ChiCTR2000029851	α-Lipoic acid (ALA)	To evaluate the clinical efficacy and safety of α-Lipoic acid (ALA) for critically ill patients with COVID-19.
22 April 2020	medRxiv	Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis	Rapid review and meta-analysis	China	Shuya Lu et al	https://www.medrxiv.org/content/10.1101/2020.04.17.20064469v1	N/A	Glucocorticoids	To systematically retrieve and summarize the current evidence of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19
26 April 2020	MedRxiv	A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections	Systematic review	UK	Khan et al	https://www.medrxiv.org/content/10.1101/2020.04.23.20076612v1.full.pdf	N/A	Anakinra, Tocilizumab, Sarilumab, Siltuximab	To assess the effectiveness of specific interleukin-1 and -6 inhibitors for the treatment of coronavirus-related infections.
13 April 2020	Press release	Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND	Preliminary results from clinical trial	USA	CytoDyn INC.	https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for	NA	leronlimab	Could leronlimab be effective?
28 February 2020	Aging and Disease	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia	CT	China	Leng et al.	http://dx.doi.org/10.14336/AD.2020.0228	ChiCTR2000029990	ACE2-mesenchymal stem cell	Efficacy of MSC transplantation in COVID patients
26 March 2020	Journal of Medical Virology	Tocilizumab treatment in COVID-19: a single center experience	Observational study	China	Luo et al.	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25801	NA	tocilizumab	What are treatment responses of TCZ in the COVID-19 patients?
17 April 2020	Circulation Research	Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19	Observational study	China	Zhang et al.	https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134	NA	Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)	To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension
23 April 2020	JAMA	Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection inWuhan, China	Case series	China	Juy Li, et al	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049	NA	Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)	Asses the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.
PrePrint	Acta Pharmaceutica Sinica B	Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19	RCT	China	Xiaoyan Liu, et al.	https://www.sciencedirect.com/science/article/pii/S2211383520305529	NA	Dipyridamole	Is treatment with dipyridamol clinically effetive in severly ill COVID19 patients?

18 April 2020	medRxiv	Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials	meta-analysis of RCTs	China/ USA	Jing Wang et al	https://www.medrxiv.org/content/10.1101/2020.04.13.20064295v1.full.pdf		chloroquine/hydroxychoroquine	To evaluate the efficacy and safety of Chloroquine and hydroxychloroquine
20 April 2020	medRxiv	Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 2 - Hand hygiene and other hygiene measures: systematic review and meta-analysis.	systematic review and meta-analysis	Saudi Arabia, Australia, Canada	Al-Ansary	https://www.medrxiv.org/content/10.1101/2020.04.14.20065250v1.full.pdf	NA	hygiene interventions	To assess the effectiveness of hand hygiene, surface disinfecting, and other hygiene interventions in preventing or reducing the spread of illnesses from respiratory viruses
17 April 2020	medRxiv	An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area	Clinical trial	China	Meng et al.	https://www.medrxiv.org/content/10.1101/2020.04.11.20061473v1.full.pdf	NCT04320238	Recombinant human interferon-alpha nasal drops	To investigate the efficacy and safety of recombinant human interferon alpha1b (rhIFN-α) nasal drops in healthy medical staff to prevent COVID-19.
23 March 2020, updated 15 April 2020	medRxiv	An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)	RCT	China	Li et al.	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2.full.pdf	NCT04252885	lopinavir/ritonavir (Kaletra), arbidol	Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment
17 April 2020	medRxiv	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis	review and meta-analysis	China	Shi et al.	https://www.medrxiv.org/content/10.1101/2020.04.13.20064436v1.full.pdf	NA	antivirals	To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children.
17 April 2020	medRxiv	Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review	rapid review	China	Wang et al	https://www.medrxiv.org/content/10.1101/2020.04.13.20064402v1.full.pdf	NA	antibiotics	The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19
Preprint	Médécine et Maladies Infectieuses	No evidence of rapid antiviral clearance or clinical ben-efit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection	Prospective virological assay	France	JM Molina et al.	https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub	NA	Hydroxychloroquine, azithromycin	Is hydroxychloroquine effecitve for viral clearance when reproducing the study of Gautrel et al.?
Accepted 31 March 2020	Journal of Infection	The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis	Meta-analysis	China	Zhenwei Yang, et al.	https://www.sciencedirect.com/science/article/pii/S0163445320301912?via%3Dihub	Grant from the National Natural Science Foundation of China (Jing Liu, grant no. 81472735) and the Wuhan University (Jing Liu, grant no. 2042019kf0206	Corticosteroids	Evaluate the influence of corticosteroids in patients with coronavirus.
Preprint	Clinical Infectious Diseases	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients	Prospective PK study	France	Sophie Perinel et al,	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa394/5816960	NA	Hydroxychloroquine	What is the best dose of hydroxychloroquine for COVID19 patients?
	Journal of Molecular Cell Biology	Treating COVID-19 with Chloroquine	RCT	China	Mingxing Huang, et al.	https://academic.oup.com/jmcb/article/doi/10.1093/jmcb/mjaa014/5814655	NA	Chloroquine, lopinavir, ritonavir	Is cholorquine better than lopinavir/ritonavir in severe and moderate COVID19 patients?
10 April 2020	NEJM	Compassionate Use of Remdesivir for Patients with Severe Covid-19	Report	UK, Canada, Europe, Japan	Grein et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2007016	NA	Remdesivir	NA
10 March 2020	Journal of Critical Care	A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19	Systematic review	Italy	Andrea Cortegiani, et al.	https://www.sciencedirect.com/science/article/pii/S0883944120303907?via%3Dihub	NA	Chloroquine	Summary of the existing the evidence on chloroquine for the treatment of COVID-19
Preprint	Journal International AIDS Society	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment	Systematic review	Switzerland	N Ford et al.	https://onlinelibrary.wiley.com/doi/10.1002/jia2.25489	NA	Antiretroviral drugs	Systematic review of the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials
30 March 2020	Complementary Therapies in Clinical Practice	Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study	Non-interventional RCT	China	Kai Liu, et al.	https://www.sciencedirect.com/science/article/pii/S1744388120304278	Ethics committees of Hainan General Hospital and Huanggang Central Hospital (approval numbers: 19758 and 20200125)	Respiratory rehabilitation training	Investigate the effects of 6-week respiratory rehabilitation training on respiratory function, QoL, mobility and psychological function in elderly patients with COVID-19
6 March 2020	Complementary Therapies in Clinical Practice	Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19	Non-interventional RCT	China	Kai Liu, et al.	https://www.sciencedirect.com/science/article/pii/S1744388120302784	NA	Progressive muscle relaxation (sleep therapy)	Investigate the effect of progressive muscle relaxation on anxiety and sleep quality of COVID-19 patients
24 March 2020	MedRxiv	First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients	CT	China	Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf	NCT04291729	danopevir/ritonavir	Effect of danoprevir in moderate COVID-19 patients
07 April 2020	MedRxiv	The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study	Retrospective CT	China	Chen Shi et al.	https://www.medrxiv.org/content/10.1101/2020.03.28.20046144v2	not found	enoxaparin	Efficacy of enoxaparin
14 April 2020	MedRxiv	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial	Retrospective analysis	France	Matthieu Mahévas et al.	https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf	NA	Hydroxychloroquine	To assess the effectiveness of Hydroxychloroquine in patients with severe Covid-19

27 March 2020	JAMA	Treatment of 5 critically ill patients with COVID-19 with convalescent plasma	Observational study	China	C Shen, et al.	https://jamanetwork.com/journals/jama/fullarticle/2763983	Grants: National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development Project	Convalescent plasma	Is plasma from convalescente patients beneficial for critically ill COVID19 patients?
6 April 2020	Proceedings of the National Academy of Sciences of the United States of America	The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study	Observational/retrospective control	China	Kai Duan et al	https://www.pnas.org/content/early/2020/04/02/2004168117	ChiCTR2000030048	Convalescent plasma	Is treatment with convalescent plasma safe and beneficial for COVID19 patients?
Preprint	Influenza and other Respiratory Viruses	Medical Masks vs N95 Respirators for Preventing COVID-19 in Health Care Workers. A Systematic Review and Meta-Analysis of Randomized Trials	Systematic review	Canada	Jessica J Bartoszko, et al.	https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12745	NA	N95 respirators vs surgical masks	Compare medical masks to N95 respirators in preventing laboratory confirmed viral infection and respiratory illness including coronavirus specifically in health care workers.
Preprint	Disaster Medicine and Public Health Preparedness	RANDOMIZED TRIAL OF INSTRUCTOR-LED TRAINING VERSUS VIDEO LESSON IN TRAINING HEALTH CARE PROVIDERS IN PROPER DONNING AND DOFFING OF PERSONAL PROTECTIVE EQUIPMENT	RCT	Denmark	L Christensen et al	https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/article/randomized-trial-of-instructorled-training-versus-video-lesson-in-training-health-care-providers-in-proper-donning-and-doffing-of-personal-protective-equipment/CF08F4727DA9D536883ECBFD04BC2570	NA	Training on personal protective equipment	Is attending one live training session or watching video trainings over a month more effective for training on downing and doffing personal protective equipment?
Preprint	Journal of Medical Virology	Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department	Diagnostic assay	Italy	Irene Cassantini et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25800	NA	Diagnostic serological assay	To assess an easy to perform serological assay for diagnosis of COVID19
Preprint	Joural of Clinical Microbiology	Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2	Diagnostic assay	China	Wanbing Liu, et al.	https://jcm.asm.org/content/early/2020/03/27/JCM.00461-20	DOI: 10.1128/JCM.00461-20; Hospital Ethics Committee of the General Hospital of the Central Theater Command 107 of the PLA ([2020]003-1)	Diagnostic serological assay	Evaluate the diagnostic feasibility of two ELISA assays
Article originally published in 2015; authors added comment on 30/03/2020	BMJ Open	A cluster randomised trial of cloth masks compared with medical masks in healthcare workers	RCT	Australia /Vietnam	MacIntyre CR et al.	https://bmjopen.bmj.com/content/5/4/e006577	Australian New Zealand Clinical Trials Registry: ACTRN12610000887077.	medical masks, cloth masks	To compare the efficacy of cloth masks to medical masks in hospital healthcare workers
31 March 2020	MedRxiv	Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial	RCT	China	Zhaowei Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2	ChiCTR2000029559	Hydroxychloroquine	Assess the efficacy of hydroxychloroquine
Preprint		Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study	RCT	France	Gautret et al.	https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf	NA	Hydroxychloroquine, Azithromycin	Assess the efficacy of hydroxychloroquine associated with azithromycin
23 March 2020 (preprint, not yet peer-reviewed)	BMJ	An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)	RCT	China	Li et al.	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1	NCT04252885	lopinavir/ritonavir (Kaletra), arbidol	Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment

10 Feb 2020	Biosci Trends	Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.	Summary of 15 CTs	China	Gao et al.	https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_article	ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and ChiCTR2000029	Chloroquine	Could chloroquine be effective?
30 March 2020	not published yet	Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients	Preliminary results from clinical trial	USA	CytoDyn Inc.	https://www.cytodyn.com/newsroom/press-releases/detail/401/three-additional-patients-with-severe-covid-19-treated-with	NA	Leronlimab	Could leronlimab be effective?
27 March 2020	medRxiv	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial	RCT	China	Chang Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2	ChiCTR2000030254	Favipiravir, Arbidol	Conventional therapy + favipiravir or arbidol?
20 March 2020	International Journal of Antimicrobial Agents	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	CT	France	Gautret et al.	https://www.sciencedirect.com/science/article/pii/S0924857920300996#!	EudraCT number 2020-000890-25	Hydroxychloroquine, Azithromycin	Role of hydroxychloroquine on respiratory viral loads
19 March 2020	N Engl J Med	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.	RCT	China	Cao et al.	https://www.ncbi.nlm.nih.gov/pubmed/32187464	ChiCTR2000029308	lopinavir/ritonavir (Kaletra)	Lopinavir-Ritonavir combination compared to conventional therapy ?
11 March 2020	Journal of Infection	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study	Retrospective cohort study	China	Lisi Deng	https://www.sciencedirect.com/science/article/pii/S0163445320301134?via%3Dihub	NA	Lopinavir/ritonavir, Arbidol	Arbidol and lopinavir-ritonavir compared to lopinavir-ritonavir only?
In press	British Journal of Anaesthesia	High-flow nasal-oxygenation- assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial	RCT	China	Cai-Neng Wu et al.	https://bjanaesthesia.org/article/S0007-0912(20)30135-5/fulltext	ChiCTR2000029658	High-flow nasal oxygnation	What is the efficacy and safety of high-flow nasal oxygenation during fibreoptic bronchoscopic intubation in critically ill patients with COVID-19?
2020 Pre-print online	Chinese Journal of Infectious Diseases,	Efficacy of lopinavir, ritonavir and Arbidol for the treatment of new coronavirus pneumonia	Retrospective analysis	China	Chen Jun et al.	http://rs.yiigle.com/yufabiao/1182592.htm	NA	Lopinavir/ritonavir, Arbidol	Efficacy of lopinavir/ritonavir and arbidol
2020	Journal of Zhejiang University (Medical Science) 2020 , Vol. 49 Issue (1)	A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)	RCT	China	Chen Jun et al.	http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03	NCT04261517	Hydroxychloroquine	Role of hydroxychloroquine on respiratory viral loads
2020 Pre-print	MedRxiv	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	CT	China	Huijie Bian et al.	https://doi.org/10.1101/2020.03.21.20040691	NCT 04275245	Meplazumab	Assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
Total									